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Abstract 
Tuberculosis (TB) is a major global health problem, especially in the developing 
world. In order to end the TB epidemic, reliable and rapid diagnostic tools that can 
identify and discriminate between latent and active TB are required. In addition, the 
emergence of multi- and extensively drug resistant strains of Mycobacterium 
tuberculosis (Mtb) highlights the need of improved treatment regimens and tools for 
monitoring the effect of treatment. It has been suggested that adjunct treatment that 
targets the host response to infection has the potential to facilitate eradication of Mtb, 
reduce tissue inflammation and shorten the treatment duration. 
The main aim of this thesis was to characterise immune cells and soluble immune 
markers in different stages of TB infection with focus on identifying potential 
biomarkers that may improve TB diagnostics and monitoring of treatment efficacy. 
The secondary aim was to explore the in vitro effects of the potential adjunct 
treatment option cyclooxygenase (COX)-inhibition on Mtb specific T cell responses.  
Peripheral blood mononuclear cells, plasma and supernatants from the 
QuantiFERON-TB Gold (QFT) test were obtained from individuals with active and 
latent TB before and during TB treatment and from QFT-negative controls. T cell 
subsets were studied by flow cytometry and potential immune modulating effects of 
the COX-inhibitor indomethacin on Mtb specific T cell responses were examined in 
vitro. Multiple soluble markers were measured in plasma and QFT supernatants by 
multiplex and enzyme immunoassays. 
In paper I, we found that the level of regulatory T cells (Treg) was higher in both the 
active and latent TB group compared with controls. The results of paper IV indicate 
that the COX-inhibitor indomethacin may be used to modulate the immune response 
in active TB by reducing the number of Mtb specific Treg.  
In paper II, we report that the plasma level of interferon gamma inducible protein 10 
(IP-10), although not specific for TB, may differentiate between active and latent TB 
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irrespective of human immunodeficiency virus (HIV) infection and may also be used 
to monitor the effect of treatment.  
In paper III, we did not find any marker with potential to differentiate between active 
and latent TB infection when Mtb specific marker levels were analysed in QFT 
supernatants. However, Mtb specific interleukin (IL)-1ra, IL-2 and IP-10 levels 
distinguished individuals with borderline QFT test results from QFT negative 
controls and these markers may improve the differentiation between latent TB and 
non-TB infected individuals. 
In conclusion, the results support that Treg may be a target for adjunct host directed 
therapy in TB, and that Mtb specific Treg can be reduced by COX-inhibitors which 
are well known drugs approved for other clinical conditions. Potential biomarkers for 
TB diagnosis and treatment efficacy have been identified. However, further studies 
are needed to examine whether it is possible to establish sufficient sensitive and 
specific test cut-offs for use in clinical practice. 
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1. Introduction 
Tuberculosis (TB) is an infection caused by Mycobacterium tuberculosis (Mtb) and is 
together with human immunodeficiency virus (HIV) and malaria among the leading 
causes of death from infectious diseases worldwide [1]. There is currently no optimal 
vaccine available. Strategies for TB control aim to reduce transmission by 
identification and treatment of infectious cases as well as offering preventive therapy 
to individuals with latent TB. An “End TB strategy” including intensified research 
and innovation has been developed by the World Health Organization (WHO) and 
aims to reduce the TB incidence rate by 90% within 2035 [2].  
1.1 The tuberculosis epidemic 
The WHO estimates that one third of the world’s population has latent TB and in 
2015 there were an estimated 10.4 million new cases of active TB and 1.8 million TB 
deaths [1]. 1.2 million of the cases and 0.4 million of the deaths were in HIV-positive 
individuals. There are great geographical variations both in the incidence of TB 
(figure 1) and in the prevalence of HIV in new TB cases. The majority of the cases, 
61%, occurred in the South-East Asia and Western Pacific regions. The African 
region with 26% of the cases had the most severe burden relative to population and in 
addition had the highest proportion of HIV-positive TB cases. 
The TB incidence has fallen by an average of 1.5% per year since 2000 and the 
WHO’s Millennium development goal of halting and reversing the TB epidemic by 
2015 has been met in all six WHO regions. However, the decline needs to accelerate 
to reach the milestone of the end TB strategy and the emergence of multi- and 
extensively drug resistant (MDR and XDR) strains of Mtb has aggravated the TB 
epidemic. In 2015, an estimated 3.9% of new TB cases had MDR-TB, and 9.5% of 
these were XDR-TB. India, China and the Russian Federation accounted for 45% of 
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the MDR-TB cases, and the proportion of new TB cases with MDR-TB varies from 
0-6 % in most countries to >20% in areas of the former Soviet Union. 
In Norway, TB was a high-endemic disease at the end of the 18th century. As a result 
of improvements of living conditions and the availability of anti-tuberculous drugs 
from the 1940s, the incidence declined and was at the lowest level in 1996 with 201 
reported cases [3]. The last decade, the incidence of active TB cases has been 300-400 
per year [3]. TB cases among Norwegian-born individuals are now rare and variations 
in the incidence are associated with the number of immigrants from high-endemic 
countries. A nationwide study of MDR-TB in Norway from 1995-2014 found that 
MDR-TB is rare in Norway and is predominantly seen in immigrants from the Horn 
of Africa and countries of the former Soviet Union [4]. 
Figure 1. Estimated TB incidence rates, 2015. Adapted from WHO global 
tuberculosis report 2016 [1]. 
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1.2 The clinical course of tuberculosis
TB infection is acquired by inhalation of aerosol droplets expelled from individuals 
with active pulmonary TB. Primary TB infection is usually asymptomatic, and in 
most individuals the immune response is sufficient to constrain the infection. 
However, the primary infection foci may harbour viable bacteria in a latent state for 
years until reactivation and progression to active disease.  
In exposed individuals, Mtb infection can be detected by development of an antigen-
specific T cell response. Latent TB is defined by WHO as “a state of persistent 
immune response to stimulation by Mtb antigens without clinically manifested active 
TB” [5]. The lifetime risk of developing active TB from latent TB is estimated to 5-
15% [1], and most commonly, reactivation occurs within a few years after the initial 
infection [6]. Predisposing factors like HIV coinfection, anti-tumour necrosis factor 
(TNF) treatment, diabetes, malnutrition and other immunosuppressive conditions 
increase the risk of reactivation considerably [7]. It is estimated that the risk of 
developing active TB is 26 times greater in HIV-positive individuals compared to 
HIV-negative individuals, and TB is the leading cause of death among HIV-positive 
individuals [8].  
Pulmonary TB is the most common manifestation of active disease. Typically there is 
a gradual onset of symptoms including fever, cough, malaise, anorexia and weight 
loss. Extrapulmonary TB constituted about 15% of the 6.1 million TB cases notified 
in 2015 [1], and is more frequent in HIV co-infected individuals [9]. Organs typically 
involved are the lymph nodes and pleura, but any organ system can be affected. 
Miliary TB is a condition with widespread dissemination of Mtb giving millet-like 
lesions in the involved organs. 
Traditionally, TB infection has been categorised either as latent or active, where 
latent TB constitutes an asymptomatic condition with containment of inactive 
bacteria and active TB constitutes active replication of bacteria giving clinical 
disease. However, neither of the diagnostic tests available for latent TB infection 
provides any direct evidence of the presence of viable bacteria and while progressing 
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from latent to active disease, patients often undergo asymptomatic stages with only 
radiological or bacteriological manifestations indicating active disease [10,11]. It is 
suggested that the responses to TB infection is better understood as a continuous 
spectrum with sterilizing immunity and fulminant active disease at the extremes 
(figure 2) [6,8].  In this model, the old concept of latent TB includes individuals with 
sterilizing immunity as well as individuals with active replicating bacteria at a 
subclinical level. The model is supported by results from imaging studies using 
positron emission tomography (PET) and computed tomography (CT) showing that 
individuals with latent TB display a range of findings which in part correspond to 
observations in patients with active TB [6]. 
Figure 2. The spectrum of TB-from Mtb infection to active (pulmonary) disease. 
Reprinted by permission from Macmillan Publishers Ltd:  Nature Reviwes Disease 
primers, Pai M.[8]. Copyright 2016. 
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1.3 Immune responses against Mycobacterium tuberculosis
Complex interactions between Mtb and the host including both innate and adaptive 
immune responses contribute to the defence against Mtb. In active TB, the immune 
response limits mycobacterial replication and dissemination, but also causes 
formation of granulomas, tissue necrosis and cavitation. The balance between the 
protective and pathological effects of the immune response determines the outcome 
of the infection.  
1.3.1 Innate immune responses 
The innate immune response is the first line of defence against Mtb and is important 
in promoting the generation of adaptive immune responses. However, innate immune 
cells are also manipulated by Mtb to serve as niches for bacterial replication and to 
delay priming of adaptive immune cells [12]. 
After inhalation, Mtb reaches the alveolar space where it interacts with dendritic cells 
(DCs) [13,14], macrophages and pulmonary epithelial cells [15,16]. The macrophage 
is the primary host cell of Mtb which enters through receptor-mediated phagocytosis. 
Complement and mannose receptors on the surface of the macrophage are the main 
receptor groups involved in phagocytosis [17]. The macrophages also express several 
other pattern-recognition receptors, including Toll-like and C-type lectin receptors, 
that recognise Mtb components and induces the expression of cytokines and 
chemokines that are essential for eliciting the adaptive immune response [18]. To be 
able to persist and survive within the macrophages, Mtb has evolved multiple 
strategies to evade their antimicrobial mechanisms [19]. 
DCs have an important role in initiating the adaptive immune response by priming of 
naïve lymphocytes [20], and are also involved in the induction and expansion of 
regulatory T cells (Treg) [21]. Migration of DCs to the regional lymph nodes is 
critical in the immune response against Mtb [22], and infection of DCs by Mtb leads 
to upregulation of the antigen presenting molecules major histocompatibility complex 
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(MHC)-1 and MHC-2 in addition to co-stimulatory molecules [23,24]. However, it 
has also been reported that Mtb impairs the function of DCs by decreasing the ability 
of infected DCs to activate T cells and delaying their migration to the lymph nodes 
[22,25]. Blood DCs are categorised into myeloid (mDCs) and plasmacytoid DCs 
(pDCs) based on differences in phenotype and function [20]. mDCs secrete IL-12 and 
induce Th1 immune responses whereas pDCs secrete interferon alpha (IFN- ) and 
induce Th2 responses [26]. It has been found that the absolute numbers of both DC 
subsets are decreased in patients with active TB compared to controls and that the 
numbers are restored following successful anti-tuberculous therapy [27]. 
Monocytes are found in the circulation and during infection and inflammation they 
traffic to inflamed tissues were they differentiate and supply the tissues with 
macrophages and dendritic cells [28,29]. It has been demonstrated that infected 
monocyte derived DCs are essential for the transport of Mtb to the local lymph node 
[30], and humans with a certain genotype of the macrophage chemoattractant protein 
(MCP)-1 promoter gene, which are important in monocyte trafficking, have increased 
susceptibility to TB infection [31]. Increased susceptibility has also been associated 
with the ratio of monocytes to lymphocytes in blood [32]. Monocytes can be divided 
into subsets based on cell surface markers and it has been demonstrated that cluster of 
differentiation (CD)16+ monocytes are expanded in patients with active TB and 
correlates with disease severity [33]. As CD16+ monocytes are refractory to DC 
differentiation [34], less resistant to Mtb intracellular growth and less prone to 
migrate than CD16- monocytes, the expansion in CD16+ monocytes may promote 
microbial resilience [35]. However, the relative importance of monocyte subsets in 
human TB remains to be defined [25].   
1.3.2 Adaptive immune responses 
Since Mtb is an intracellular pathogen the adaptive immune response is 
predominantly dependent on cell-mediated immunity. In humans, the adaptive 
immune response to Mtb is detectable approximately 3-8 weeks after exposure [36].
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CD4+ T cells 
The CD4+ T cell subset is essential for protection against Mtb which is clearly 
demonstrated by the increased risk of development of active TB in HIV-positive 
individuals [37,38]. The increased risk is observable as early as HIV seroconversion 
and further increases as CD4+ T cell levels decrease, while immune reconstitution by 
antiretroviral therapy (ART) reduces the risk [39]. 
 The CD4+ T cell response is mainly a Th1 response characterised by expression of 
the cytokines interferon gamma (IFN- ) and interleukin (IL)-2. IFN-  plays a central 
role in activating macrophages and their antimicrobial functions, and humans with 
defects in the IFN-  and IFN- -receptor genes are highly susceptible to Mtb infection 
[40]. IL-2 promotes the expansion and differentiation of T cells into effector and 
memory cells [41]. In addition, Mtb induces T cell expression of TNF-  which act 
synergistically together with IFN-  to stimulate production of nitric oxide and other 
reactive nitrogen intermediates by macrophages [42].  
Regulatory T cells 
Treg are a subset of  T cells that may impair immune responses necessary for 
adequate control of infection, but also limit excessive inflammation causing tissue 
damage [43]. The mechanisms of Treg mediated immune suppression is incompletely 
understood, but includes secretion of inhibitory cytokines and cell contact dependent 
mechanisms [44].  Patients with active TB have reduced purified protein derivative 
(PPD) stimulated production of IFN-  compared with tuberculin skin test (TST) 
positive healthy individuals  [45], and it has been suggested that Treg contribute to 
the suppression of the Th1 immune responses [46]. Increased numbers of Treg have 
been observed in active TB infection, both at the sites of infection and in blood [46–
51], and there seems to be a correlation between the severity of the infection and the 
number of Treg [51–53]. Several studies have reported a decline in the frequency of 
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Treg during TB treatment [54–56], whereas others have found sustained [47] or 
initially increased levels [57].  
Studies of Treg in mouse models of TB have shown that Mtb specific Treg expand 
early during infection, delay the onset of adaptive immunity and are eliminated after 
the initial phase of infection [58,59]. Although Treg are considered to have a negative 
effect during the initial stage of infection, it is not known to which degree Treg are 
detrimental versus beneficial during active TB disease [60]. Treg cell depletion 
studies in mice has shown that efficient depletion of Forkhead box P3 (FOXP3)+ 
Treg cells decrease the bacterial burden in Mtb-infected lungs, but also lead to robust 
autoimmune activation [61]. Studies using other strategies for Treg depletion based 
on the marker CD25 have shown contradictory results. Quinn et al reported no impact 
on bacterial load when Treg numbers were reduced using anti-CD25 antibodies [62], 
whereas Kursar et al found a lower bacterial load when Treg levels was reduced in a 
model using adoptive transfer of  CD25+ T cells into T cell deficient mice [63]. The 
contradictory results may be due to the limitations of CD25 as a Treg marker (Treg 
markers are discussed in section 4.2.4).
A review have discussed the potential of Treg as a target for immunotherapeutic 
strategies to improve T cell responses and vaccine efficacy [64]. It has been shown 
that depletion of CD4+ Treg significantly improves the protective capacity of the 
Bacillus Calmette-Guérin (BCG) vaccine [65] and it is suggested that vaccine 
designing methodologies must consider suppression of different Treg for enhancing 
vaccine efficacy as well as search for Mtb antigen epitopes that will selectively 
suppress Treg. Immunotherapeutic strategies targeting Treg may also improve 
favourable host responses during Mtb infection. However, extreme caution is 
emphasized when considering Treg manipulation because of their dual role in the 
immune response [64].  
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CD8+ T cells 
A requirement for CD8+ T cells in the immune response against Mtb has not been 
proven in humans, but animal model data support a non-redundant and complex role 
for CD8+ T cells [66]. In humans there is no equivalent condition with loss of CD8+ 
T cells as the loss of CD4+ T cells in HIV-positive individuals, and information on 
the contribution of CD8+ T cells in TB infection is therefore mainly based on mouse 
models. Studies of knockout mice have shown that classically restricted CD8+ T cells 
are necessary for control of infection [67,68], and depletion of CD8+ T cells in the 
chronic stages of infection in mice leads to a substantial increase in bacterial burden 
[69]. Mtb specific CD8+ T cells have been detected in humans with active TB and in 
healthy contacts [70]. These cells are able to secrete IFN-  in response to stimulation 
with Mtb-infected targets and have cytolytic activity [71,72].  Rozot et al found that 
Mtb specific CD8+ T cells responses were detected in 60% of patients with active TB 
compared with only 15% of subjects with latent TB infection [73] and a combination 
of both CD4+ and CD8+ T cell responses may improve the diagnostic tools of active 
TB [74]. 
B cells and humoral immunity 
It is generally thought that B cells and humoral immunity play an important role in 
host defence against extracellular pathogens, whereas control of intracellular 
pathogens relies on cell-mediated immunity [75]. Since Mtb is an intracellular 
pathogen, the role of B cells and humoral immunity in TB infection has been 
controversial and is less defined than the role of T cells [76]. However, there is 
increasing evidence that B cells and antibodies has a significant impact on the 
immune response against Mtb by both classical and non-classical mechanisms of 
antibody action and interaction of B cells with other immune cells [76].  
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1.3.3 Immune correlates of protection against Mycobacterium tuberculosis  
It is not clear what constitutes a protective immune response against Mtb infection.
The lack of an immune correlate of protection hampers vaccine development as 
empirically determining whether a vaccine reduces the number of active TB cases is a 
daunting task. 
Despite being essential in the immune response against Mtb, CD4+ T cell production 
of IFN-  does not correlate with protection [77]. Polyfunctional (IFN- +TNF- +IL-
2+)  T cells are considered to be superior effectors compared with single producing T 
cells [78], and have been associated with control of chronic viral infections [79–81]. 
Studies of the cytokine profiles of Mtb specific CD4+ T cells by flow-cytometry have 
shown that TNF-  single producing cells dominates in active TB whereas 
polyfunctional (IFN- +TNF- +IL-2+) T cells characterise latent TB [82,83]. 
However, other studies have found contradictory results with increased levels of 
polyfunctional cells in active compared with latent TB [84,85], and an immune 
correlate study in BCG vaccinated infants found no correlation between the 
frequency and cytokine profile of Mtb specific T cells with protection against TB 
[86]. Further, a recent study reported that the frequency of activated human leukocyte 
antigen-D related (HLA-DR)+CD4+ T cells is associated with increased TB disease 
risk in BCG vaccinated infants and in Mtb infected adolescents, and that BCG 
specific IFN-  producing T cells were a correlate of protection [87].  Due to the 
contradictory results of single markers, a review has suggested that a broad 
characterisation of immune mediators and cell types, including mechanisms that 
appear to have minor roles, is needed to define protective immunity and that an 




In 2015, only 56% of the estimated incident active TB cases were notified [1]. This is 
explained by under-reporting of diagnosed TB cases and under-diagnosis. The main 
reasons for under-diagnosis is poor access to health care facilities, the often 
unspecific clinical presentation of the infection and the lack of an affordable, simple 
and accurate point-of-care diagnostic test. TB diagnosis is especially difficult in HIV 
co-infected individuals as HIV changes the presentation of active TB disease and 
affects the performance of the available diagnostic tools [8]. 
1.4.1 Diagnosis of latent tuberculosis  
There is no gold standard for diagnosing latent TB. The tests available are based on 
detection of an acquired immune response upon rechallenge with antigen and do not 
give any direct information about the presence of viable bacteria. For nearly a 
century, the TST was the only tool available for detection of latent TB. The TST 
measures the induration caused by a delayed type hypersensitivity response to PPD 
injected intradermally. Limitations of the TST include poor sensitivity in 
immunocompromised individuals and poor specificity because PPD contains antigens 
also present in the BCG vaccine and non-tuberculous mycobacteria (NTM). Efforts 
have been made to develop new more specific skin test by replacing PPD with more 
specific antigens, but higher specificity might compromise sensitivity [88].
Blood based in vitro assays that measure IFN-  released by T cells in response to 
stimulation with Mtb antigens (interferon gamma release assays (IGRAs)) was 
developed the past decade. Commercially available IGRAs include the 
QuantiFERON-TB Gold (QFT) and the T-SPOT.TB (figure 3). In the QFT assay 
whole blood is drawn into three QFT tubes containing TB antigen, mitogen-positive 
control and a negative control respectively. After incubation, an enzyme-linked 
immunosorbent assay (ELISA) is conducted to quantify the amount of IFN-
produced in the antigen tubes compared with the control tubes. The test is considered 
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positive if the IFN-  response to TB antigens is above the cut-off after subtracting the 
background IFN-  response in the negative control. The T-SPOT.TB is an enzyme-
linked immunospot (ELISPOT) assay based on separated peripheral blood 
mononuclear cells (PBMCs). After incubation with TB antigens and a negative and 
positive control, the result is reported as the number of IFN- -producing T- cells, and 
as for the QFT assay, the background in the negative control is subtracted from the 
result of the TB antigen stimulated cells.  
The IGRAs are more specific than the TST because the TB antigens used (ESAT-6 
and CFP-10, and in QFT also TB7.7(p4)) are not shared with the BCG vaccine strain 
or most NTM. As for the TST, the sensitivity in HIV-positive individuals and in 
children is suboptimal [89,90]. Further, the use of IGRAs in resource limited settings 
is limited by high costs and need of laboratory facilities. QFT-Plus is a next 
generation IGRA launched in 2015 which include an additional TB antigen tube [88]. 
The second TB antigen tube contains peptides designed to elicit a response from 
CD8+ T cells and the aim is to increase the sensitivity of the test.  
In contrast to the TST, the IGRAs can be repeated without any sensitisation or 
boosting which make them more applicable for repeated screening. However, studies 
of IGRAs for serial TB screening of health care workers [91,92] and in HIV infection 
[93,94] have shown that the interpretation of IGRA results is complicated by relative 
high rates of conversions and reversions and within subject variability. Subjects with 
QFT baseline results around the diagnostic cut off (0.35 IU/mL) are more likely to 
have inconsistent results on serial testing and introduction of a borderline zone from 
0.20-0.70 IU mL when screening health care workers have been suggested [91].  
Neither TST nor IGRAs can distinguish between active and latent TB. They also have 
limited prognostic value as most TST and IGRA-positive individuals will not 
progress to active TB [95]. New biomarkers are required to distinguish between the 
different stages of infection and to guide the use of preventive therapy to the 
subgroup that most likely will benefit from it.  
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Figure 3. The test procedures of the QFT and T-SPOT.TB assays. Reprinted from 
The Lancet Infectious Diseases, Vol 12, Pai et al, Interferon-gamma assays in the 
immunodiagnosis of tuberculosis: a systematic review, pp 761-76 [96], Copyright 
(2004), with permission from Elsevier. 
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1.4.2 Diagnosis of active tuberculosis 
Diagnosis of active TB traditionally relies on smear microscopy and culture of Mtb
from clinical samples. Despite poor sensitivity and inability to distinguish between 
Mtb and NTM, microscopy is still widely used and is the mainstay of active TB 
diagnosis in resource limited settings. The sensitivity ranges from 20-80% and is 
lowest in HIV-positive individuals and in children [97].  
Culture is the gold standard for diagnosing active TB. Mtb is growing slowly and 
detection of growth using traditional solid media requires incubation for 3-8 weeks. 
Automated liquid culture systems have decreased the detection time to 1-3 weeks and 
have higher sensitivity, but the contamination rates are higher, they are expensive and 
require considerable laboratory facilities [98]. 
In 2010 WHO recommended the use of a recently developed nucleic acid 
amplification-based test, the Xpert MTB/RIF, for detection of pulmonary TB. In 
2013, a policy update widened the recommended use to also include diagnosis of 
paediatric TB and for selected extrapulmonary specimens [99]. The Xpert MTB/RIF 
enables rapid and simultaneous detection of Mtb and rifampicin resistance and 
clinical trials have shown that use of the Xpert/MTB/RIF assay increases the numbers 
of patients identified compared with smear microscopy and decreases the time to 
initiation of treatment [100]. However, the assay is expensive, and no significant 
impact on patient morbidity and mortality has been reported [100,101]. As with smear 
microscopy, the sensitivity is lower in HIV-positive individuals and children, and for 
extrapulmonary samples the sensitivity varies with sample type [102]. In addition to 
the Xpert MTB/RIF, two other nucleic acid amplification-based tests have been 
endorsed by WHO for detection of drug resistance, the GenoType MTBDRplus and 
the NTM+MDRTB tests [103]. These tests detect resistance against both isoniazid 
and rifampicin, but are only validated for testing of smear positive specimens or 
isolates of Mtb [102,103]. 
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1.5 Treatment
The first antibiotic with activity against Mtb, Streptomycin, was discovered in 1944. 
However, it soon became evident that monotherapy lead to development of drug 
resistance. The following two decades several other antituberculous drugs with 
different mechanisms of action were discovered including isoniazid, pyrazinamide, 
rifampicin and ethambutol, and it was shown that combination therapy reduced the 
risk of drug resistance. The standard drug regimens currently recommended for drug 
susceptible TB still relies on the drugs discovered in the 1950s and 1960s. Efforts 
have been made to develop new anti-tuberculous drugs, and in 2012-2014 two new 
drugs were approved for treatment of MDR-TB when an otherwise effective regimen 
is not available [104].  
1.5.1 Treatment of latent tuberculosis  
Preventive treatment of individuals with latent TB infection reduces the risk of 
developing active TB [105]. There are several recommended regimens including six 
or nine months isoniazid alone, three-four months isoniazid plus rifampicine, three-
month weekly rifapentine plus isoniazid and three-four months rifampicin alone 
[5,106]. Benefit of treatment must be balanced against risk of drug-related side-
effects, and testing and preventive therapy is therefore offered to individuals with the 
highest risk of progression to active disease. In high and middle-income countries, 
WHO recommends systematic testing and treatment of latent TB in contacts of 
pulmonary TB cases, individuals with HIV coinfection, patients starting anti-TNF 
treatment, patients receiving dialysis, patients preparing for organ transplantation and 
patients with silicosis [5]. In resource limited settings, testing and treatment of latent 
TB is recommended for HIV-positive individuals and children < five years of age 
who are close contacts of people with pulmonary TB [107]. 
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1.5.2 Treatment of active tuberculosis 
The standard treatment regimen for new TB patients with drug susceptible TB 
currently consist of a two month intensive phase with rifampicin, isoniazid, 
pyrazinamide and ethambutol, and a four month continuation phase with rifampicin 
and isoniazid [106,108]. To ensure patient compliance and prevent development of 
drug resistance, the treatment is given as directly observed treatment (DOT). 
MDR-TB is defined as TB caused by Mtb strains resistant to at least rifampicin and 
isoniazid. XDR-TB in addition involves resistance to any of the fluoroquinolones and 
to at least one of the three second line drugs amikacin, capreomycin and kanamycin. 
MDR- and XDR-TB cases require extended treatment regimens with combinations of 
drugs that increase the risk of serious side effects. The two new anti-tuberculous 
drugs, bedaquiline and delamanid are promising for MDR-TB treatment. However, 
access in high burden countries is limited and there are unresolved safety concerns 
with bedaquiline [109]. Globally,  the treatment success rate for new TB cases treated 
in 2014 were 83%, whereas the corresponding  rates for MDR- and XDR-TB cases 
were only 52% and 28% respectively [1].  
1.5.3. Host directed therapy 
The low treatment success rates for MDR- and XDR- TB highlight the need of 
improved treatment strategies. Adjunct treatment that targets the host response to 
infection (host directed therapies (HDTs)) have been suggested to may facilitate 
eradication of Mtb, shorten treatment duration and reduce permanent lung injury by 
augmenting cellular antimicrobial mechanisms and reducing excessive inflammation 
[110,111]. The range of potential targets and candidate HDTs is broad (figure 4) and 
includes several well-known drugs approved for other clinical indications.  
Cyclooxygenase (COX)-2 inhibitors reduce the production of prostaglandin E2 
(PGE2) which has a key role in the generation of the inflammatory response. In 
addition to proinflammatory properties, PGE2 is involved in suppression of T cell 
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functions [112–114] and both monocytes and adaptive Treg seem to supress T cell 
immune responses by a COX-2-PGE2 dependent mechanism [115,116]. 
In mouse models of TB it has been shown that treatment with COX-2 inhibitors 
enhances Th1 cytokines and reduces inflammation and bacillary loads [117–120]. 
However, the effect of COX-inhibition is phase dependent as a beneficial effect of 
PGE2 has been reported in the early, but not late phase of TB infection [119,121]. 
Clinical trials in HIV-positive patients have shown that COX-2 inhibitors improve T 
cell mediated immune responses [122–124].  The effect of COX inhibition in human 
TB has not been published, but studies are ongoing (ClinicalTrials.gov Identifier: 
NCT02503839 and NCT02781909).
Figure 4. Potential targets of host-directed therapy against Mtb.  Yellow boxes 
indicate pathological processes. Blue boxes indicate points of intervention by host-
directed therapies. Reprinted by permission from  Macmillan Publishers Ltd: Nature 
reviews Immunology, Wallis R.S. [110], copyright (2015). 
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1.5.4. Monitoring treatment efficacy 
In pulmonary TB cases, sputum culture conversion (SCC) status at the end of the two 
month intensive phase of treatment is the most well established predictor of non-
relapsing cure [125]. The two-month SCC status is also associated with treatment 
success in MDR-TB patients, but the association is substantially stronger for six-
month SCC [126]. As culture is not always available in high burden settings and, 
especially on solid media, takes several weeks to give a result, SCC status has not 
been widely used clinically [127].  
WHO currently recommends smear microscopy at completion of the intensive phase 
of treatment to identify individuals at risk of poor treatment outcome [108]. Sputum 
smear microscopy status is a poor predictor with respect to which patients will 
relapse, but are used to trigger further patient assessment and additional sputum 
monitoring. 
Several studies have investigated the potential of IGRAs for monitoring effect of 
treatment. A review found no uniform pattern in IGRA conversion and reversion 
rates at the end of treatment for active and latent TB, and concluded that IGRAs are 
unlikely to be useful for monitoring effect of TB treatment [128]. In most of the 
studies reviewed, the majority of the IGRA results remained positive at the end of 
treatment. In a subsequent longitudinal study of HIV-positive individuals with latent 
TB, the QFT reversion rate was 23% for individuals receiving preventive therapy and 
44% in individuals with untreated latent TB, supporting the unreliability of QFT for 
treatment monitoring [94].
Nucleic acid amplification based tests, like the Xpert MTB/RIF are not suitable for 
monitoring treatment because they detect DNA from both viable and non-viable 
bacteria [129]. However, it has been suggested that pre-treatment of samples with 
propidium monoazid allows selective amplification of DNA from viable Mtb [130].   
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New accurate and rapid tools for monitoring of treatment efficacy would be a major 
advance as it would simplify TB drug treatment trials and prevent inadequate 
treatment that further may lead to transmission from subsequent reactivation.  
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1.6 Potential biomarkers for tuberculosis diagnosis and 
treatment efficacy 
A biomarker can be defined as a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes or 
pharmacologic responses to a therapeutic intervention [131]. In TB, biomarkers are 
needed for multiple purposes including diagnosis of the different stages of infection, 
identification of individuals with high risk of progression to active disease, 
monitoring of treatment efficacy and evaluation of the protective efficacy of vaccines 
[132]. The ideal diagnostic TB test would be an affordable point-of-care test 
providing accurate diagnosis of active TB in both HIV-negative and HIV-positive 
individuals with pulmonary and extrapulmonary TB and detection of drug resistance 
to the first-line anti-tuberculous drugs [132]. 
Biomarkers in infectious diseases can be either host- or pathogen derived. In TB, an 
example of a pathogen derived biomarker is lipoarabionmannan (LAM) which is a 
component of the outer wall of Mtb that is released from metabolically active or 
degrading cells and is detectable in urine. In contrast to other diagnostic tools, the 
sensitivity of urine LAM for active TB detection is increased in HIV co-infected 
individuals compared to HIV-negative individuals and further increases with lower 
CD4 counts [133]. A point-of-care lateral flow dipstick for urinary LAM detection is 
commercially available (LF-LAM) and may be used to assist in the diagnosis of TB 
in HIV-positive adults with low CD4 counts [134].  
Host response derived biomarkers for TB diagnosis and treatment efficacy have been 
sought using technologies like transcriptomics, proteomics and multiplex bead 
assays. The blood transcriptional signatures and proteomic profiles for active TB 
reported are heterogeneous and currently there are no diagnostic assays based on 
these techniques available [135]. Biomarkers have also been searched for among the 
multiple cytokines and chemokines expressed as a part of the immune response 
against Mtb (figure 5) [136,137]. Both unstimulated plasma and in vitro Mtb specific 
stimulated levels of various markers have been investigated in the different stages of 
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TB infection in a number of explorative studies. A review by Chegou et al
summarizes that although several new potential cytokine biomarkers to detect Mtb 
specific immunity have been identified, there is no clear pattern of markers able to 
differentiate between active and latent TB infection [136]. Similarly, a review 
concludes that although several cytokines have potential to monitor TB treatment, no 
single cytokine or combinations of cytokines have been shown to provide a 
sufficiently robust correlate of treatment success [137]. The diverse results emphasize 
the need of larger confirmatory studies to validate the diagnostic potential of the 
suggested biomarkers. There is also lack of studies including HIV co-infected 
individuals in whom the current diagnostic tools have the greatest limitations. 
Figure 5. Overview of key cells and cytokines involved in the immune response 
towards Mtb specific antigens in immunodiagnostic tests. Reprinted by permission 
from European respiratory society. Chegou NN, European Respiratory journal, 2014 
[136].  
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Interferon gamma inducible protein 10 (IP-10) is one of the most studied candidate 
biomarkers in TB. It is a chemokine secreted by antigen presenting cells and can be 
induced at high levels as part of the adaptive immune response. Secretion is driven by 
multiple cytokines, but mainly by IFN-  and TNF- [136]. It has been found that 
plasma levels of IP-10 are elevated in patients with active TB [138–140], as well as in 
patients with other inflammatory conditions like bacteremia [141], infection with HIV 
[142,143] and hepatitis C virus [144].  Several studies have reported a decrease in 
plasma levels of IP-10 in response to TB treatment of HIV-uninfected active TB 
cases [138,140,145–147], whereas there are conflicting results in HIV co-infected 
cases [146,147]. As a readout marker in Mtb specific immunoassays, IP-10 has 
comparable diagnostic accuracy to IFN- [148]. The relative high levels of IP-10 
secreted compared with other biomarkers have made it possible to develop simplified 
detection methods based on dried blood/plasma spots which performs comparably to 
the QFT [149–151].  
TNF-  plays a central role in the immune response against Mtb which is 
demonstrated by the increased risk of reactivation of latent TB in patients receiving 
anti-TNF treatment [152]. Soluble TNF receptors (sTNFr) act as TNF antagonists by 
competing with the cell membrane receptors for cytokine binding, and elevated 
plasma levels of both sTNFr1 and sTNFr2 have been found in patient with active TB 
[153]. 
Pentraxin 3 (PTX3) and C-reactive protein (CRP) belong to the pentraxin family and 
are involved in the acute phase reaction to inflammation. It has been shown that 
mycobacterial LAM induces PTX3 production by human monocytes [154]. Further, 
Azzuri et al found that plasma levels of PTX3 are increased in patients with active 
TB, decreases during successful treatment and increases in patients with treatment 
failure [138]. CRP is produced in the liver and is extensively used as a marker of the 
extent of inflammation. As for PTX3, CRP levels decrease during successful TB 
treatment [155,156]. 
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The Th1 cytokine IL-2 is mainly produced by antigen-activated T cells but at a lower 
magnitude compared with IFN- . TB antigen specific stimulated levels of IL-2 have 
comparable diagnostic accuracy for active TB as IFN-  and IP-10 [136], and a meta-
analysis concludes that IL-2 is also a valid marker for diagnosing latent TB and 
combined with IFN-  may increase sensitivity [157]. 
IL-1 receptor antagonist (IL-1ra) is a competitive inhibitor of the proinflammatory 
cytokines IL-1  and IL-1  and is secreted by various cells including monocytes, 
macrophages and neutrophils [158].  Juffermans et al showed that serum levels of IL-
1ra are increased in patients with active TB compared with contacts and controls and 
declined during treatment [153]. Further, studies have shown that when detected in 
QFT supernatants, IL-1ra differentiate TB infected individuals from controls 
[159,160] and may also differentiate active from latent TB infection [159]. 
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2. Aims 
The main aim of this thesis was to characterise immune cells and soluble immune 
markers in different stages of TB infection with focus on identifying potential 
biomarkers that may improve TB diagnostics and monitoring of treatment efficacy. 
The secondary aim was to explore the in vitro effects of COX-inhibition on Mtb 
specific T cell responses. 
The specific aims were: 
• To examine levels of Treg, activated CD4+ and CD8+ T cells and DC subsets 
in blood from individuals with active TB, latent TB and QFT-negative controls 
(paper I). 
• To examine the potential of soluble immune markers detected in plasma to 
differentiate between the stages of TB infection in patients with and without 
HIV coinfection, and to study the effect of TB treatment on levels of these 
markers (paper II). 
• To examine the potential of soluble immune markers detected in QFT 
supernatants to differentiate between the stages of TB infection, and to 
compare the pattern of markers in subjects with a QFT test result in the 
borderline zone with those with higher values and with QFT negative controls 
(paper III). 
• To analyse COX-2 expression in monocytes from patients with latent and 
active TB, and to explore the in vitro effects of the COX–inhibitor 
indomethacin on Mtb specific T cell responses (paper IV). 
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3. Summary of papers 
3.1 Paper I: T Regulatory cells and immune activation 
in Mycobacterium tuberculosis infection and the effect of 
preventive therapy 
The levels of Treg, DC subsets and activated CD4+ and CD8+ T cells in blood from 
patients with active TB, latent TB before and after three months of preventive therapy 
and from QFT-negative controls were examined by flow cytometry. 
The level of Treg, identified as CD25+CD127-, was significantly higher in both the 
active and latent TB group compared with the controls. Further, the active TB group 
had the highest median level of CD25+FOXP3+ Treg although there were no 
significant differences between any of the groups. Increased T cell activation of both 
CD4+ and CD8+ T cells, represented by higher proportion of HLA-DR+CD38+ cells, 
was found in the active TB group and there was a significant positive correlation 
between the level of activated CD4+ T cells and both Treg subsets. There were no 
significant differences in the proportion of mDCs or pDCs among the study groups 
and no correlation between DC and Treg subsets. The level of CD25+FOXP3+Treg 
significantly increased in the latent TB group after preventive TB therapy, whereas 




3.2 Paper II: IP-10 differentiates between active and latent 
tuberculosis irrespective of HIV status and declines during 
therapy 
In this study we searched for plasma biomarkers with potential to differentiate 
between the stages of TB infection in HIV-negative and HIV-positive individuals, 
and examined changes in biomarker levels during TB treatment of HIV-negative 
patients with active TB by ELISA and multiplex bead assays. 
Of the 38 markers examined, IP-10 and sTNFr2 were the only markers that 
significantly differentiated active TB from both latent TB and QFT negative controls 
irrespective of HIV status. The level of IP-10 declined gradually and significantly in 
response to TB treatment of HIV-uninfected active TB cases, whereas the level of 
sTNFr2 fluctuated. 
The diagnostic accuracy of IP-10 was investigated by receiver operating 
characteristics (ROC) curve analyses. In HIV-infected individuals IP-10 
discriminated active from latent TB with 100% sensitivity and specificity, whereas in 




3.3 Paper III: Cytokine patterns in tuberculosis infection; IL-
1ra, IL-2 and IP-10 differentiate borderline QuantiFERON-
TB samples from uninfected controls
Using a multiplex bead assay, we searched for biomarkers in QFT supernatants with 
potential to differentiate between the various stages of TB infection and examined the 
pattern of markers in subjects with QFT test result in the borderline zone. In addition, 
we examined changes in marker levels after preventive TB therapy. 
The unstimulated (Nil) level of IL-1 , IL-1ra, IL-9 and IL-17a were significantly 
lower in the active TB compared with the latent TB group. In contrast, the 
background corrected TB antigen stimulated (TBAg-Nil) levels of none of the 27 
markers analysed were able to differentiate between these groups. 
The TBAg-Nil level of seven markers was significantly higher in both the active TB 
and latent TB group than in QFT negative controls. However, only IL-1ra, IL-2 and 
IP-10 also differentiated the QFT borderline group from the controls. Using cut-offs 
determined by ROC curve analyses, the majority of the subjects were classified in 
accordance with the QFT test by all these three markers. There were no significant 
changes in the Nil or TBAg-Nil levels of any of the markers with diagnostic potential 
after preventive TB treatment of the latent TB group. 
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3.4 Paper IV: The COX- inhibitor indomethacin reduces 
Th1 effector and T regulatory cells in vitro in 
Mycobacterium tuberculosis infection 
We studied COX-2 expression in monocytes from patients with latent and active TB 
and explored the in vitro effects of the COX-inhibitor indomethacin on Mtb specific 
T cell responses and regulation. 
Although not statistically significant, unstimulated monocytes from patients with 
active TB tended to express higher levels of COX-2 compared to individuals with 
latent TB. Monocytes from both the latent and active TB group significantly 
upregulated COX-2 expression after in vitro lipopolysaccharide (LPS) stimulation. 
In response to ESAT-6 and Ag85 stimulation there was a significant increase in 
FOXP3+CD25++ Treg and proliferating and cytokine (IL-2, TNF- , IFN- ) 
producing T cells. Indomethacin significantly reduced the fraction of 
FOXP3+CD25++ Treg, but also the fraction of total IL-2 producing and total TNF-
producing CD4+ T cells as well as the proliferative capacity of T cells in Mtb antigen 
stimulated samples. 
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4. Methodological considerations 
4.1 Study design and participants 
The studies which constitute this thesis are comparative retrospective studies 
including comparisons of patients with active TB, individuals with latent TB and TB 
negative controls. In addition, the studies of paper I, II and III include longitudinal 
data on selected study groups, and paper IV an exploratory cross-sectional in vitro
study of patients with active TB. An overview of the study designs, number of 
participants, methods and factors investigated are given in table 1. 
Table 1. Overview of study design, number of study participants, methods and 
factors investigated 
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In paper I, III and IV, all the study participants were HIV-negative. In paper II, the 
study participants were further classified according to HIV status. An overview of the 
sample size in each subgroup in paper II is given in table 2. 
Table 2. Overview of the sample size of the study groups in paper II 
4.1.1. Inclusion of study participants 
The study participants in paper I and III were recruited at Haukeland University 
Hospital (HUH) in the period 2006-2007. Individuals referred to the TB outpatient 
clinic for medical evaluation of latent or active TB based on a positive TST and/or 
suspected exposure to TB were included as part of a study of the performance of 
IGRA in clinical practise [161]. In addition, patients diagnosed with active TB were 
recruited from the inpatient ward, and QFT and TST negative controls were recruited 
from age-matched employees at the hospital with no known exposure to TB.  
The study population in paper II comprised participants included from clinical studies 
at different hospitals in Norway. In addition to the participants recruited at HUH 
described above, HIV-positive individuals were included from a national IGRA 
multicentre study in the period 2009-2010 [162]. HIV-negative patients with active 
TB followed longitudinally during 24 weeks of TB treatment were included from a 
clinical study at Oslo university hospital (OUS) in the period 2009-2012 [57].  
The study population in paper IV comprised participants recruited at HUH described 
above and active TB patients recruited at OUS in the period 2010-2014. 
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4.1.2 Definition of study groups 
1. Active TB.  
Active TB cases were defined by the presence of Mtb detected by culture, or by the 
presence of clinical and radiological or histopathological signs of active disease.  
2. Latent TB.  
Subjects with a positive QFT, no signs of active TB based on X-ray, sputum 
examination and clinical evaluation and no previous active TB were defined as 
having latent TB.  
3. Controls 
Subjects with a negative QFT, no signs of active TB and no previous active TB 
served as TB negative controls. 
4.1.3. Limitations of study design  
In general, the sample size in the studies comprising this thesis is low. This is mainly 
due to the low TB prevalence in Norway and logistical difficulties in inclusion of 
patients and sample processing. The limitations in study groups and sample size for 
each paper are specified below.  
Paper I 
Due to logistical difficulties at HUH, we were not able to collect blood samples from 
the active TB group at the end of therapy or to perform longitudinal blood sampling 
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from QFT-negative subjects. We were therefore not able to investigate the effect of 
treatment on Treg, DC and activated CD4+ and CD8+ in the active TB group or to 
evaluate longitudinal variation in these factors in the QFT negative control group. 
Paper II 
There was a low prevalence of active TB in the HIV-infected population from whom 
the study participants were recruited [162]. The sample size of HIV-infected patients 
with active TB in the study is therefore especially low, and there is also a lack of 
longitudinal plasma samples from this group during treatment. Further, as plasma IP-
10 is an unspecific marker for TB, the study should ideally have included both an 
HIV–positive and HIV–negative group with infections and inflammatory diseases 
other than TB. 
Paper III 
Repeated testing of subjects with QFT test result in the borderline zone was not 
performed and we were therefore not able to examine the variability of potential 
biomarkers in longitudinal samples. 
Paper IV 
Due to a limited number of samples and PBMCs available from the latent TB group, 
the effects of indomethacin on Mtb specific Treg and T cell cytokine production and 
proliferation was only studied in patients with active TB where we believed the 
effects would be most pronounced and relevant. 
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4.2 Laboratory assays 
4.2.1 Processing and storage of samples 
Blood samples were drawn from the study participants at defined time-points and 
PBMCs were cryopreserved to enable simultaneous batch analysis of multiple 
samples. It has been shown that cryopreserved cells can be stored for at least 12 years 
with no tendency of cell loss or decrease in viability over time [163], and that the 
functionality of CD4+ and CD8+ T cells are unaffected by cryopreservation in 
cytokine ELISPOT assays [164]. However, it has also been reported that 
cryopreservation can cause changes in the frequencies and function of T cell 
subpopulations [165,166].  
The quality of cryopreserved PBMCs is highly dependent on optimal 
cryopreservation and thawing methods and a number of factors including time until 
processing and storage and thawing temperatures affect the results [167]. In general, 
PBMCs with viability 70% are considered suitable for functional analyses [168]. 
Despite the use of standardized cryopreservation and thawing protocols some of the 
samples in our study had low viability after thawing and these were excluded from 
further analyses. 
Plasma and excess of supernatants from the QFT test were frozen and stored at -80°C 
until analysis. Long term storage can cause degradation of cytokines even at -80°C 
[169]. In our study, the majority of the cytokines analysed in both plasma and QFT 
supernatants had levels detectable above the lower detection limit of the Multiplex 
bead assays.  
4.2.2 Flow cytometry 
Flow cytometry has the capability of measuring several parameters of thousands of 
single cells per second which allows detailed analysis of cell surface and intracellular 
markers. The basic principles of flow cytometry are shown in figure 6. Cells are 
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stained with fluorochrome conjugated antibodies to the markers of interest and pass 
through a laser beam one by one. Forward and side scattered light and emitted light 
from the fluorochromes passes through a system of filters and mirrors to route 
specific wavelengths to designated optical detectors. Flow cytometry is widely used 
to study cell subsets and antigen specific T cell responses. However, several aspects 
of the protocols used need careful consideration to ensure reliable assays. 
Figure 6. The basic principles of flow cytometry. Reprinted by permission from 
abcam [170].  
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Multicolour detection 
Advances in technology and availability of fluorochrome conjugated antibodies have 
increased the number of parameters possible to detect, but with increasing number of 
markers also the number of fluorochromes with overlapping spectra increases. 
Spillover occurs when fluorescence emission from a fluorochrome is detected in a 
detector designed to measure the signal from another fluorochrome. This lead to false 
signals and compensation must be performed to correct multiparameter flow 
cytometric data for spectral overlap [171]. Still, it’s important to avoid spillover from 
bright cell population into detectors requiring high resolution sensitivity [172]. In our 
flow cytometry assays, the maximum number of fluorochromes used was eight and 
the assays were optimized according to Mahnke et al [173]. Bright fluorochromes 
were chosen for weak antigens, and antibody conjugates were titrated to determine 
optimal concentrations. Compensation beads or PBMCs were used to prepare single 
stained compensation controls.  
Gating and defining regions 
Analysis of flow cytometry data involves gating on the cells of interest (figure 7). 
Differences in gating may be the largest contributor to variability in flow cytometry 
data [174]. Some markers, as CD3, CD4 and CD8, give discrete positive and negative 
populations that are easily discriminated from each other. However, for several 
markers such as CD25 and FOXP3, cell populations display a more continuous 
distribution of staining intensity making the definition of regions more complicated. 
Strategies applied to guide definition of regions include use of fluorescence-minus-
one (FMO) and isotype controls or setting the cut-off based on another cell 
population within the sample having similar surface characteristics as the target 
population, but which do not express the marker of interest.  
Most flow cytometry data are described as the percentage of cells positive for a 
particular marker or set of markers. For markers having a continuous distribution it 
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may be more appropriate to report the median fluorescence intensity (MFI) of the cell 
population. In paper IV we report both the percentage of FOXP3+CD25++ cells and 
the FOXP3 MFI. 
Figure 7. Example of flow cytometry data analysis and gating. 
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Number of events 
When small subpopulations are of interest, the total number of cells acquired must 
include sufficient events of the population of interest. The number of cells acquired 
influences the precision of the analysis [175], and the number required to achieve a 
given precision can be determined by simple calculation [176]. We acquired at least 
10.000 CD4+ and CD8+ T cells for the intracellular analyses of cytokines and 
FOXP3 expression in T cells and minimum 1.000 monocytes for the analyses of 
COX-2 expression in monocytes.  
Viability staining 
Dead cells often show high levels of nonspecific binding, and exclusion of dead cells 
is particularly important when analysing rare populations. In paper IV, a fixable 
viability stain was included in all analyses. In paper I, no viability stain was included 
due to the analysis being performed on a flow cytometer allowing only five colour 
detection. The flow cytometry analyses in paper I did not include any stimulation of 
cells or detection of rare events, and occupying one of the detectors by a viability 
stain was therefore not prioritized. Dead cells were to some extent excluded by 
forward and side scatter gating. Still, optimally a viability stain should have been 
included.  
Intracellular cytokine staining assays 
Intracellular cytokine staining (ICS) assays involves stimulation and culturing of cells 
in the presence of a protein secretion inhibitor followed by surface staining, fixation, 
permeabilization, intracellular staining and flow cytometry analysis.  Published 
methods for optimization of intracellular cytokine assays [172,177] were used as 
guidelines for design of our protocols. 
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ICS is commonly used to study antigen specific T cell responses. However, variations 
between studies in the protocols used often make the results difficult to compare. In 
addition to the challenges of multicolour detection and gating, the duration of antigen 
stimulation has a significant impact on the T cell responses detected [178,179]. The 
recommended stimulation period for detection of IL-2, TNF-  and IFN-  is 6-12 
hours [172,177,180], whereas the expression of FOXP3 has been found to peak after 
36h stimulation [181]. Han Q. et al showed that initial cytokine secretion from T cells 
are predominantly monofunctional and the results indicated that simultaneous release 
of IL-2, TNF-  and IFN-  is a short-lived state [182].  
T cell responses to antigen stimulation are commonly presented as background 
subtracted, i.e. responses in the unstimulated control are subtracted from the response 
in the antigen stimulated samples. In paper IV, the main objective was to study the 
effect of indomethacin on Mtb specific T cell responses. To better delineate the effect 
of indomethacin on stimulated versus unstimulated PBMCs, the results were all 
shown without subtracting background values. Gates for intracellular cytokines was 
set based on the unstimulated sample and boolean gating strategy used to define 
single-, double- and triple cytokine positive cells.  
Carboxyfluorescein diacetate succinimidyl ester proliferation assay 
In paper IV, T cell proliferation was assessed by a carboxyfluorescein diacetate 
succinimidyl ester (CFSE) proliferation assay. CFSE is an intracellular fluorescent 
dye which is equally distributed to the daughter cells following cell division [183]. 
Cell surface and intracellular markers can be measured in the same assay allowing 
analyses of proliferation of specific lymphocyte subsets. The cut-off for proliferating 
cells was set to the peak of the second generation of CFSEdim CD4+ or CD8+ T cells.
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4.2.3 Markers of T cells, activation, apoptosis, dendritic cells and 
monocytes 
An overview of the markers of T cells, Treg, activation, apoptosis, DCs and 
monocytes used in paper I and IV is given in table 3. CD3 in combination with CD4 
and CD8 are used as key markers to identify T helper and T cytotoxic cells 
respectively. CD3 is expressed by T cells only, whereas CD4 and CD8 also are 
expressed by other immune cells. 
In paper I, T cell activation was assessed by expression of CD38, HLA-DR and CD28 
and apoptosis by expression of CD95. CD38, HLA-DR and CD95 are upregulated 
following T cell activation whereas CD28 is transiently down regulated [184–187]. 
DCs were characterized by a Lineage 1 (CD3, CD14, CD16, CD19, CD20 and CD56) 
negative HLA-DR+ phenotype and further classified as CD11c+  mDCs or CD123+ 
pDCs which differ in origin and function [20,26]. 
In paper IV, monocytes were identified using the markers CD14, CD16 and HLA-DR 
according to the gating strategy described by Abeles et al [188], and COX-2 
expression analysed. Th1 type T cell responses were evaluated by intracellular 
staining of IFN- , IL-2 and TNF- .  
Table 3. Markers of T cells, activation, apoptosis, DCs and monocytes used in 
flow cytometry assays in paper I and/or IV [189]. 
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Table 3 continued. 
Lineage 1   
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4.2.4 Regulatory T cell markers 
Treg were first identified by expression of CD25 and the cells with high expression of 
CD25 were shown to have the greatest suppressive function [190]. However, CD25 is 
also expressed by activated non-regulatory T cells [191], and the continuous 
distribution of staining intensity make the definition of the CD25 expression level 
required to define the Treg population difficult. The transcription factor FOXP3 has 
been identified as a more specific marker for Treg being crucial for their development 
and function [192], but may also be up-regulated following activation [193,194] and 
since FOXP3 is an intracellular marker, the necessity of fixation/permeabilization 
protocols precludes isolation of viable cells. An additional marker, CD127, which 
allows isolation of viable Treg for assessment of functional capacity, has also been 
introduced [195]. As a substantial fraction of CD25+CD127- Treg do not express 
FOXP3 and a small proportion of CD25+FOXP3+ cells retain high expression of 
CD127 [196,197], it has been suggested that these markers do not represent the same 
population of Treg [197]. Further, gating of a clear CD25+CD127- population has 
been considered more difficult than gating of CD25+FOXP3+ T cells [197,198]. In 
2015, an international workshop group proposed that CD3, CD4, CD25, CD127 and 
FOXP3 are the minimally required markers to define human Treg [199]. Further, it 
was proposed to use CD3+CD4- cells to define the limits of the CD25 gate as this 
strategy results in objective CD25+ gating rather than subjective gating on 
CD25high/CD25++ cells. 
In paper I, frequencies of both CD25+FOXP3+ and CD25+CD127- Treg were 
examined whereas in paper IV only CD25++FOXP3+ Treg were studied. The 
methods used to set the limit for the CD25 and the FOXP3 gate differed between the 
two papers. In paper I, the FOXP3 gate was set based on the CD4 negative 
population, and the CD25 gate to include all CD25 positive cells based on isotype 
controls. In paper IV, the FOXP3 gate was set visually as the positive and negative 
population was clearly separated, and the CD25 gate was set to include only the 
CD25high (CD25++) cells. Due to limited numbers of PBMCs available we were not 
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able to perform sorting of Tregs for further assessment of their immunosuppressive 
capacity. 
4.2.5 Multiplex bead assays 
Multiplex bead assays are based on flow cytometry and enable simultaneous 
measurement of multiple analytes in a small sample volume. The basic principles of 
multiplex beads assays are shown in figure 8. Distinctly coloured bead sets are 
created by the use of two fluorochromes at distinct ratios, and antibodies to a specific 
analyte is attached to a set of beads with the same colour. A second antibody to the 
analyte is conjugated to a reporter fluorochrome. 
Figure 8. The basic principles of multiplex bead assays. Reprinted with permission 
from Bio-Rad [200]. 
In paper II and III, a multiplex cytokine assay was used to detect levels of 27 
different markers in plasma and QFT supernatants, respectively. The 27 markers 
included in the assay are listed in table 4. When analysing markers with a wide range 
of concentrations simultaneously it can be a problem to determine optimal dilutions 
allowing detection of all analytes within the range of the assay. In paper III, we 
experienced that some of the markers analysed had concentrations above the upper 
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detection limit (UDL) of the multiplex assay despite fourfold dilution of the samples. 
On the other hand, the level of one of the markers was below the lower detection 
level (LDL). In paper II nine of the markers were below the LDL (Table 4). 




ELISA are in contrast to multiplex bead assays only able to detect the level of a 
single analyte in each assay and requires a higher sample volume per analyte 
measured [201]. ELISA is a plate-based technique in which the wells are coated with 
an antibody to the analyte of interest. The analyte is detected by a second antibody 
linked to an enzyme that generates a coloured product when chromogenic substrate is 
added. The intensity of the colour is proportional to the amount of analyte captured in 
the well, and the result can be assessed by a plate reader.  
In paper II, ELISA was used to detect plasma levels of CXCL16, PTX3, sTNFr2, Fas 
Ligand (FasL) thymus and activation regulated chemokine (TARC)/CCL17, 
osteoprotegerin (OPG), activated leukocyte cell adhesion molecule (ALCAM), IL-23, 




Nonparametric statistic tests were used in all four papers. Mann-Whitney U test was 
used to detect pairwise differences between groups, whereas Wilcoxon sign rank test 
was used to compare related samples. Correlations were investigated using 
Spearman’s rank correlation coefficient. In paper II, we applied a binary logistic 
regression model to evaluate whether the markers examined were able to differentiate 
between the study groups when adjusted for HIV-status, age and sex. In paper II and 
III, ROC curve analyses were performed on selected markers to determine optimal 
cut-off levels for differentiation between the study groups. 
There are two main limitations in the statistical analyses performed. Firstly, the 
sample sizes in paper I-IV are relatively small which increases the risk of type II 
errors, i.e. incorrectly retaining a false null hypothesis. Secondly, multiple testing 
increases the risk of type I errors, i.e. incorrect rejection of the null hypothesis, and 
was an issue in all studies. There is no gold standard or consensus on how to handle 
multiple comparisons. The Bonferroni adjustment of significance level is developed 
for independent tests, and is too conservative when tests are dependent.  In paper I-III 
we performed preliminary analyses of the correlation between the variables 
investigated. In general, we found that many of the variables were highly correlated 
leading to dependent tests and the significance level used were therefore adjusted 
more moderately than by Bonferroni. Also in paper IV we examined partially highly 
correlated variables. However, in this paper we chose to show the statistical analysis 
in a simple manner without adjusting the significance level. 
  
58
4.4 Ethical considerations  
Written informed consent was obtained from all participants. The studies were 
approved by the respective Regional Committees for Ethics in Medical Research 
(REK-Vest, REK-Nord and REK-Sør-øst). Plasma, QFT supernatants and PBMCs 
were stored in approved biobanks at Department of medicine, HUH and OUS 
(“Research Biobank Infectious diseases”). 
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5. General discussion 
In this project we have characterised immune cells and soluble immune markers in 
different stages of TB and explored the in vitro effects of immune modulation by cox-
inhibition on Mtb specific T cell responses. The results improve the understanding of 
the immune mechanisms involved in the spectrum of TB infection, and potential 
candidate biomarkers for TB diagnosis and monitoring of treatment efficacy have 
been identified. 
5.1. T cell and monocyte activation in the different stages 
of tuberculosis  
In concordance with previous studies [202,203], we found increased levels of 
activated T cells in the active TB group compared with controls. Further monocytes 
from patients with active TB tended to express higher levels of COX-2 compared to 
patients with latent TB. The latent TB group showed a large variation in the levels of 
activated T cells, overlapping with values found both in the active and the QFT 
negative control group. Although monocytes from the majority of individuals with 
latent TB expressed very low levels of COX-2, two out of nine had monocytes with 
considerable elevated COX-2 expression. One may speculate that the variation in 
immune cell activation in the latent TB group is associated with the suggested 
understanding of TB infection as a spectrum of responses where latent TB includes 
individuals with sterilizing immunity as well as individuals with controlled infection 
or active replicating bacteria at a subclinical level [6]. Our data thereby may indicate 
that immune activation gradually increases throughout the various stages of TB 
infection corresponding to the level of bacterial burden. This is supported by a study 
of Sullivan et al of HIV-positive individuals showing gradually elevated T cell 
activation in individuals with latent and active TB compared with TB negative 
controls [204]. We found no differences in the proportion of DC subsets among the 
study groups suggesting that the balance between mDCs and pDCs are maintained 
although absolute numbers may be decreased in patients with active TB [27].  
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5.2. The role of regulatory T cells in the different stages of 
tuberculosis  
The role of Treg in the different stages of TB infection has not been clarified. In 
paper I, we found an increased level of CD25+CD127- Treg in both the active and 
latent TB group compared with controls. However, when Treg were characterized as 
CD25+FOXP3+, we found no significant differences between any of the groups 
although the median level was higher in the active TB group. Previous studies have 
reported significantly higher levels of CD25+FOXP3+ T cells or FOXP3 mRNA 
expression in active TB compared with both uninfected controls [46,50,51] and 
individuals with latent TB [48,49].  In contrast, Chiacchio et al found comparable 
levels of CD25highFOXP3+ T cells in active TB cases and healthy controls, and also 
no significant difference in CD25highCD127- T cells between these groups [205]. 
The variation in results may, to some extent, be explained by differences in gating 
strategies and that CD127- and FOXP3+ characterize partially different populations 
of Treg [196,197]. 
Information on Treg levels or FOXP3 expression in latent TB infection compared 
with healthy controls has been scarce and only represented by a study showing higher 
FOXP3 mRNA expression in response to PPD in TST positive vs TST negative 
individuals [206]. However, a subsequent study by Herzman et al has found similar 
frequencies of CD25+CD127- Treg in blood from individuals with latent TB and 
healthy controls, but increased levels in bronchoalveolar lavage from latent TB 
individuals [207]. Recently, Serrano et al reported no differences in various Treg 
subset in blood between QFT positive and QFT negative individuals, except from a 
significantly higher level of CD39+CD127- cells in QFT+ individuals [208].  
When assessing changes in Treg levels in response to preventive therapy, we found a 
significant increase in CD25+FOXP3+ Treg, whereas there were no significant 
changes in the level of CD25+CD127- Treg. The significance of the increase in 
CD25+FOXP3+ Treg is not clear. Several studies have reported a decline in the 
frequency of Treg during TB treatment of active TB cases [54–56], whereas others 
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have found sustained [47] or initially increased levels [57]. Increased Treg levels have 
also been found in persons with previously treated extrapulmonary TB [209]. It has 
been suggested that this may be explained by redistribution of redundant Treg to 
peripheral blood from local sites of infection in response to reduced Mtb load and 
inflammation during TB therapy [57].   
Incongruent with the presumed suppressive effect of Treg, we observed a significant 
positive correlation between the level of activated CD4+ T cells and both 
CD25+FOXP3+ and CD25+CD127- Treg. The immunosuppressive function of the 
Treg identified in paper I was not assessed, whereas others have found that depletion 
of CD4+CD25high cells from PBMCs from patients with TB results in increased 
production of IFN-  upon TB antigen stimulation [46–48]. A positive correlation 
between T cell activation and Treg levels have also been found in persons with 
previous active TB [209] and in HIV-positive fast progressors [210].  
Taken together, the results indicate that Treg may have a role in both latent and active 
TB infection and is still present at the end of preventive therapy. However, there is 
variation in the results depending on the markers used for Treg characterisation. 
5.3 The potential of regulatory T cells as target for immune 
modulation by COX-inhibitors 
During infections, Treg they may be beneficial by limiting excessive inflammation 
causing tissue damage, while on the other hand, may impair immune responses 
necessary for adequate control of infection [43]. With focus on the negative effects of 
Treg, it has been suggested that they may be a target for host directed therapy [211]. 
It has been shown that PGE2 induces FOXP3 expression in CD4+CD25- T cells 
[116,212] and that this upregulation of FOXP3 and the suppressive effect of Treg are 
reversed by COX-inhibitors [116]. Several studies of Mtb infected mice have shown 
that treatment with COX-2 inhibitors enhances Th1 cytokines and reduces 
62
inflammation and bacillary loads [117–120]. However a beneficial effect of PGE2 has 
been reported in the early phase of infection [119,121], indicating that the timing of 
adjunctive therapy with COX inhibitors is critical [213]. 
In paper IV we hypothesized that the COX-inhibitor indomethacin would reduce Treg 
levels and thereby result in enhanced T cell cytokine responses and proliferation. 
Accordingly, we found that indomethacin significantly down-regulated the fraction of 
Mtb specific FOXP3+ T regulatory cells. In contrast, there was an unexpected 
concomitant decrease in Mtb induced T cell TNF-  and IL-2 production and T cell 
proliferation. This may be due to the direct effects of indomethacin on pathways other 
than COX/PGE2, e.g. the intracellular NF- B pathway [214]. NF- B is a transcription 
factor regulating genes involved  the inflammatory response [215], and it has been 
reported that COX-inhibitors inhibit NF- B activation in cell culture [216]. In our 
study COX-inhibitors thus may have a stronger inhibitory effect on Th1 effector cells 
than the presumed beneficial effect following reduced Treg numbers. As in paper I, a 
major limitation of the study is the lack of assays assessing the suppressive capacity 
of the Treg.
There is no clear definition of what constitutes protective cytokine responses in TB 
infection. Our data showed that indomethacin had a most distinct effect on the 
CD4+TNF- + T cell subset. TNF-  is essential for control of TB infection [152,217], 
but excessive production contributes to immune mediated pathology [218].  Thus, the 
effect of adjunctive therapy decreasing the cytokine response may be beneficial in TB 
patients with chronic infection and a high level of inflammation, whereas other 
patients may need an increased inflammatory response [219].  
5.4 Biomarkers for tuberculosis diagnosis  
In order to end the TB epidemic, reliable and rapid diagnostic tools that can identify 
and discriminate between latent and active TB are required. As the diagnostic use of 
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plasma levels of markers is generally limited by lack of specificity for TB infection 
we searched for alternative biomarkers in both QFT supernatants (paper III) and 
plasma (paper II). 
We showed that the plasma level of IP-10 and sTNFr2 significantly differentiates 
between active and latent TB infection irrespective of HIV-status. Our results are in 
agreement with previous studies showing elevated plasma levels of IP-10 in HIV-
negative active TB cases compared with controls [138–140], and Juffermans et al  
showing elevated sTNFr2 levels in active TB cases [153]. We reported that IP-10 had 
100% sensitivity and specificity for differentiation between active and latent TB in 
HIV co-infected individuals, whereas the results for HIV-negative individuals were 
less optimal with a sensitivity and specificity of 71% and 82%, respectively. The 
sample size, especially of HIV-positive active TB cases (n=6), in our study was 
small. A recent study by Sullivan et al which included a higher simple size also found 
higher plasma levels of IP-10 in HIV co-infected active TB cases compared with 
individuals with latent TB [204]. However, there was a noticeable overlap in IP-10 
levels in the two groups, indicating that the diagnostic accuracy of IP-10 may be less 
optimal in HIV co-infected individuals than found in our study. 
One of the main limitations of plasma levels of IP-10 is the lack of specificity for TB 
infection. In addition to in HIV infection [142,143], elevated levels have also been 
found in patients with bacteremia [141] and infection with hepatitis C virus [144]. In 
our study, two of the HIV-positive patients in the QFT negative control group had 
AIDS defining infections other than TB and had plasma levels of IP-10 that were 
above the median level of the HIV-infected active TB group. In addition, Clifford et 
al found no significant difference in serum IP-10 concentrations between patients 
with active TB and sick controls with lower respiratory tract infections caused by 
pathogens other than Mtb [220]. 
None potential biomarkers for differentiation between active and latent TB infection 
were identified when analysing background corrected TB antigen stimulated cytokine 
levels in QFT supernatants. However, the unstimulated Nil level of IL-1 , IL-1ra, IL-
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9 and IL-17a were significantly lower in the active TB compared with the latent TB 
group. Several studies of biomarkers in QFT supernatants have previously been 
performed and unstimulated or stimulated levels of various markers have been found 
to differentiate between active and latent TB infection [159,221–224]. Still, the 
results show substantial variation and a review concludes that no clear pattern of 
candidate biomarkers have been identified [136]. Our findings add to the 
heterogeneous pattern of results. Whereas we and Chegou et al [223] found lower Nil 
levels of IL-1ra in active compared latent TB, two other studies have found higher 
levels in active compared with latent TB infection [224,225].  Also for the Nil levels 
of IL-1  and IL-17a higher and not lower levels have been reported in active TB 
compared with latent TB infection [224]. Opposed to our results in plasma, the level 
of IP-10 in the Nil QFT supernatant were not able to differentiate between active and 
latent TB infection.  Other studies also show contradictory results. In a study of 
children, Chegou et al on reported that Nil levels of IP-10 differentiates between 
active and latent TB [223], whereas no differences were found in a study of adults 
[222]. 
In high and middle-income countries, WHO recommends systematic testing and 
treatment of latent TB in high risk individuals and IGRAs have been increasingly 
used for this purpose the last decade. However, the interpretation of IGRA results is 
complicated by relative high rates of conversions and reversions, and subjects with 
QFT baseline results around the diagnostic cut off (0.35 IU/mL) are more likely to 
have inconsistent results on serial testing [91–94]. When investigating the levels of 
markers in subjects with QFT test results in the borderline zone, we found that 
background corrected TB antigen stimulated levels of IP-10, IL-1ra and IL-2 
significantly differentiated this group from QFT negative controls. As there is no gold 
standard for diagnosing latent TB, the diagnostic accuracy of alternative markers is 
difficult to assess. The IL-1ra and IP-10 levels in the QFT borderline group were not 
significantly different from neither the QFT high nor the active TB group, supporting 
true TB infection in the majority of the subjects in the QFT borderline group. Further 
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studies are needed to examine the variability of IL-1ra, IL-2 and IP-10 in serial 
testing. 
5.5 Biomarkers for tuberculosis treatment efficacy 
Accurate and rapid tools for monitoring of treatment efficacy would be a major 
advance as it would simplify TB drug treatment trials and prevent inadequate 
treatment. In accordance with others, we found a decrease in plasma levels of IP-10 
during treatment of HIV negative active TB cases [138,140,145–147]. Azzuri et al
reported that plasma levels of IP-10 increased in household contacts during 
progression to active TB and during relapse of TB in patients who previously had 
completed TB treatment [138]. Further, Hong et al showed that active TB cases with 
moderate to high risk of relapse decline less in IP-10 during treatment compared with 
low risk patients [145]. Taken together, these results support the use of IP-10 as a 
biomarker for monitoring treatment efficacy.  
In contrast to IP-10, which showed a uniform decrease over time during treatment, 
the levels of sTNFr2 fluctuated, which limits its potential as a marker for monitoring 
treatment efficacy.  
Markers to confirm successful therapy are also needed for latent TB infection as 
microbiological methods and IGRAs are unhelpful [128]. We examined changes in 
markers in QFT supernatants after preventive therapy of 15 individuals with latent 
TB. However, we did not identify any potential markers for the efficacy of preventive 
therapy. Background corrected TB antigen stimulated levels of IL-2 and IP-10, in 
addition to IFN- , remained significantly higher than in the QFT negative control 




• There seems to be an increased level of T cell and monocyte activation in 
active TB, whereas large variation in the level of activated immune cells in the 
latent TB group supports the suggested understanding of TB infection as a 
continuous spectrum of disease ranging from true latency to subclinical and 
fulminant active disease.   
• Treg cells may be involved in the immune response in both latent and active 
TB infection and our in vitro data indicate that indomethacin may modulate 
immune responses in active TB by reducing the fraction of Mtb specific Treg.  
• The role of the observed indomethacin induced reduction of Mtb specific T 
cell cytokine production and proliferation is not clear and needs further 
evaluation in human models. 
• The plasma level of IP-10 has potential to serve as a biomarker for monitoring 
treatment efficacy of active TB cases. 
• Although not specific for TB, plasma level of IP-10 may give information 
about the stage of TB infection in both HIV-positive and HIV-negative 
individuals. However, it is questionable whether it is possible to establish a 
sufficient sensitive and specific test cut-off for use in clinical practice. 
• TB antigen stimulated levels of IL-1ra, IL-2 and IP-10 differentiate individuals 
with borderline QFT values from controls and may improve differentiation 
between latent TB and non-TB infected individuals. However, inconsistency 
was seen and further studies are needed to determine proper cut-offs and the 
variability of these markers in serial testing. 
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7. Future perspectives 
Early diagnosis and treatment of all people with TB are included in the key 
components of the WHO’s end TB strategy. To reach the aim of a 90% reduction in 
TB incidence by 2035, intensified research and innovation are needed to improve the 
diagnostic tools and TB treatment. 
The results of paper I and IV together with other studies of the role of Treg and 
COX/PGE2 in TB infection forms the basis for future animal studies and human 
clinical trials exploring the potential of COX-inhibitors as adjunct host directed 
therapy in TB disease. An ongoing clinical trial (ClinicalTrials.gov Identifier: 
NCT02503839) aims to study the immune effects and safety of the COX-2 inhibitor 
etoricoxib given to patients with active TB together with standard TB treatment. 
Further, another clinical trial estimating the potential efficacy and safety of using 
adjunctive ibuprofen for the treatment of XDR-TB have recently been registered 
(ClinicalTrials.gov Identifier:NCT02781909).  
We have identified potential biomarkers that may improve TB diagnostics and 
monitoring of treatment efficacy. The number of participants in our studies was 
small, but the results are still relevant for choosing candidate markers for evaluation 
in larger studies. Future studies of IP-10 for monitoring treatment of efficacy should 
include a sufficiently large number of both drug sensitive and MDR, and pulmonary 
and extrapulmonary TB cases to examine whether there are any differences in IP-10 
kinetics during treatment between these groups, and whether treatment failure are 
reflected by IP-10 levels. Larger studies are also needed to determine whether it is 
possible to establish sufficient sensitive and specific test cut-offs for the potential 
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T Regulatory Cells and Immune Activation in
Mycobacterium tuberculosis Infection and
the Effect of Preventive Therapy
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Introduction
Mycobacterium tuberculosis (TB) infection is a major global
health problem, especially in the developing world. In
2008, there were an estimated 8.9–9.9 million incident
cases and approximately 2 million deaths from TB [1]. In
addition, it is estimated that one-third of the world’s
population is infected by TB. If the immunological bal-
ance between host and pathogen is disturbed, reactivation
of latent TB infection (LTBI) and development of active
disease may occur. Globally, the human immunodefi-
ciency virus (HIV) is the most dominant risk factor for
reactivation of LTBI as well as contracting primary TB
infection.
The cellular immune system plays a pivotal role in
the immune defense against TB, and there is a critical
balance between anti-TB T cell responses and immune-
mediated pathology. TB induces a state of immune acti-
vation in the infected host, and an increased expression of
activation markers on T cells in blood from patients with
active TB has been described [2, 3]. T regulatory cells
(Treg) are CD4+ T cells involved in regulation of self-
tolerance, autoimmunity and suppression of immune
responses during infections [4, 5]. Treg cells were first
recognized as CD4+ CD25+ T cells, but expression of the
intracellular marker forkhead box p3 (foxp3) and low
cell-surface expression of the IL-7 receptor a-chain
(CD127) have been suggested as more accurate markers
[6–8]. However, recent studies have questioned whether
these markers represent different populations of Treg [9].
Patients with active TB seem to have higher levels of
CD4+CD25high+foxp3+ Treg cells in blood when com-
pared to both subjects with LTBI and uninfected controls
[10–12]. It has been shown that Treg depress T cell-med-
iated immune responses to protective TB antigens during
active TB disease [11]. The level of Treg seems to
decrease after 1 month of anti-tuberculous therapy [13].
Dendritic cells (DCs), professional antigen-presenting
cells, initiate adaptive immune responses and stimulate
induction and expansion of Treg [14]. Studies have
shown that DCs serve an important role in the initiation
and control of immune responses to TB [15]. Two DC
subsets have been characterized in blood based on
differences in phenotype markers and function; myeloid
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Abstract
Mycobacterium tuberculosis (TB) often causes persistent infection and many
immune cell subsets and regulatory mechanisms may operate throughout the
various stages of infection. We have studied dendritic cell (DC) subsets, regu-
latory T cells (Treg) and the expression of activation and apoptosis markers on
CD4+ and CD8+ T cells in blood from patients with active TB (n = 20), sub-
jects with positive QuantiFERON-TB GOLD (QFT) test (LTBI, latent TB
infection) (n = 20) before and after 3 months of preventive anti-tuberculous
therapy and from QFT-negative controls (n = 28). The frequency of CD4+
CD25+CD127) Treg was highest in the group with active TB (P = 0.001),
but also increased in the LTBI group (P = 0.006) compared to controls. The
highest level of activated T cells, defined as CD38+HLA-DR+ cells, was found
in the active TB group, for the CD4+ T cell subset positively correlated to the
level of CD25+CD127) Treg (P < 0.001, r = 0.4268). After 3 months of pre-
ventive therapy, there was an increase in the fraction of foxp3+ Treg, but no
differences in markers of activation or apoptosis. In conclusion, there seems to
be an increased level of immune activation and Treg in both latent and active
TB infection that is only modestly influenced by preventive therapy.
C L I N I C A L IMMUNO LOG Y doi: 10.1111/j.1365-3083.2010.02496.x
..................................................................................................................................................................
 2011 The Authors
234 Scandinavian Journal of Immunology  2011 Blackwell Publishing Ltd. Scandinavian Journal of Immunology 73, 234–242
dendritic cell (mDC) and plasmacytoid dendritic cell
(pDC) [16]. Decreased numbers of both DC subsets have
been found in patients with active TB when compared to
controls as well as increased pDC levels following suc-
cessful anti-tuberculous therapy [17].
There is no accurate diagnostic gold standard for
LTBI. However, the interferon-gamma release assays
(IGRA), commercially available as the QuantiFERON-
TB GOLD (QFT) and T-SPOT.TB tests, are more spe-
cific in the diagnosis of LTBI than the tuberculin skin
test (TST) because they are unaffected by Bacille Calmette
Guérin (BCG) vaccination and most infections with atypi-
cal mycobacteria. A meta-analysis including studies using
microbiologically confirmed active TB and healthy
low-risk individuals to assess sensitivity and specificity,
respectively, conclude that the QFT test offers a overall
sensitivity of 70–78% and a specificity of 96–99% when
also immune suppressed individuals are included [18].
Little is known about the distribution and role of the
various T cell and DC subsets in QFT-positive patients
and the effects of preventive anti-tuberculous therapy.
Thus, in this study, we have examined DC and Treg
subsets and the expression of activation and apoptosis
markers in CD4+ and CD8+ T cells from patients with
active TB infection, subjects with positive QFT test
before and after 3 months of preventive therapy and com-
pared to QFT-negative controls to describe immune
regulation in various stages of TB infection.
Methods
Study participants. Individuals referred to the TB outpa-
tient clinic at Haukeland University Hospital, Bergen,
Norway, for medical evaluation of latent or active TB
disease based on a positive TST and ⁄ or suspected expo-
sure of TB and patients diagnosed with active TB admit-
ted to the inpatient ward were included in the study
during the period of 2006–2007. The QFT-negative con-
trol group was also recruited from age-matched employ-
ees at the hospital with no known exposure to TB. There
were no known HIV positives among the participants
although they were not routinely tested as part of the
clinical evaluation.
The TST was performed in the primary health care
system according to standard procedures with 2 IU puri-
fied protein derivative RT 23 (2 TU) (Statens Serum
Institute, Copenhagen, Denmark) and read after 72 h.
According to national guidelines, an induration of
‡6 mm is considered a positive test [19]. The TST was
performed between one and 3 months prior to inclusion.
Overall, a total of 481 persons were referred to the TB
outpatient clinic for QFT testing and examination of pos-
sible TB infection [20]. Thoracic X-ray and clinical
examination were performed and an induced sputum
sample was obtained for acid fast staining and culture.
Blood samples for further flow cytometry analyses were
collected from randomly selected and approving individu-
als. The study subjects were classified into three groups;
(1) Active TB (n = 20), (2) QFT-positive LTBI (n = 20)
and (3) QFT-negative controls (n = 28). The ages, gen-
der, BCG vaccination status, TST result and origin are
described in Table 1.
In the active TB group, 16 patients had pulmonary
TB and four had extrapulmonary TB. There was positive
TB culture in 18 patients, whereas in two patients, diag-
nosis was based on histopathological findings in biopsies.
The patients diagnosed with active TB were given stan-
dard anti-tuberculous treatment according to national
guidelines [19]. Subjects with no signs of active TB
based on X-ray, sputum examination and clinical evalua-
tion and with a positive QFT test were defined as LTBI
and offered preventive anti-tuberculous therapy with iso-
niazid and rifampicin for 3 months. The decision to treat
was made by the clinician and the QFT test was known
at the time of decision. Blood samples for flow cytometry
analyses were obtained before start of any anti-tubercu-
lous therapy, and for the LTBI group also at the end of
therapy. Seventeen were followed with repetitive blood
sampling at the end of therapy, whereas three were lost
to follow up. 13/20 were still QFT positive, 4 ⁄20 had
turned negative whereas in 3 ⁄20 no QFT test was per-
formed. Because of logistic difficulties, we were not able
to collect blood samples from the active TB group at the
end of therapy or to perform longitudinal blood sampling
from QFT-negative subjects not starting preventive ther-
apy.
Written informed consent was obtained from all par-
ticipants. The study was approved by the Regional Com-
mittee for Ethics in Medical Research (REK) in Bergen,
Norway.
QuantiFERON-TB GOLD in-tube assay. The assay was
performed according to the manufacturer’s instructions
(Cellestis International Pty Ltd., Chadstone, Vic., Austra-
lia). One ml of whole blood was added to each of
the three QFT tubes containing TB antigen (ESAT-6,
CFP-10 and TB 7.7 [p4]), mitogen-positive control










Age, mean (range) 35 (18–82) 33 (15–65) 33 (14–59)
Males ⁄ females 13 ⁄ 7 8 ⁄ 12 8 ⁄ 20
BCG vaccinated 13 15 26
Origin from TB endemic country 16 14 2
TST, mean (range) in mm 16 (10–20) 16 (9–23) 15 (6–23)*
BCG, Bacille Calmette Guérin; TB, tuberculosis; TST, tuberculin skin
test.
*Mean and range for the twenty controls that were TST positive
(‡6 mm). In addition, eight controls were TST negative (<6 mm).
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[phytohemagglutinin (PHA)] and a negative control,
respectively. The tubes were incubated at 37 C for 16–
24 h, centrifuged and plasma removed. The amount of
interferon-gamma (IFN-c) in plasma was quantified by
enzyme-linked immunosorbent assay (ELISA). The QFT
ANALYSIS Software (Cellestis International Pty Ltd) was
used to analyse raw data (optical density values) and cal-
culate results. The level of IFN-c was corrected for back-
ground by subtracting the IU ⁄ml value obtained for the
respective negative control. The cut-off value for positive
test was ‡0.35 IU ⁄ml.
Flow cytometry analyses. Peripheral blood mononuclear
cells (PBMCs) were isolated from heparinized whole
blood using density gradient centrifugation (Lympho-
prepTM, Fresenius Kabi Norge AS, Halden, Norway),
cryopreserved in 10% dimethyl sulfoxide (DMSO) ⁄90%
foetal calf serum (FCS) and stored in liquid nitrogen
before analysis. Cryovials were thawed, washed and resus-
pended in RPMI media with 10% FCS to a final concen-
tration of 4.106cells ⁄ml. PBMC (50 ll) were incubated
for 30 min in the dark with directly conjugated mono-
clonal antibodies (mAbs) to cell-surface markers of T
lymphocytes; CD3-Phycoerythrin-Cyanin 7 (PC7) (clone
UCHT1), CD4-PC7 [clone SFCI12T4D11 (T4)], CD8-
Phycoerythrin-Cyanin 5 (PC5) (clone SFCI21Thy2D3)
(Beckman Coulter (BC), Brea, CA, USA) and CD4-fluors-
cein isothiocynate (FITC) (clone SK3) (Becton Dickinson
Biosciences (BDB), San Jose, CA, USA), activation;
CD38-phycoerythrin (PE) (clone HB7), HLA-DR-FITC
(clone L243), CD28-PE (clone L293) (BDB), CD28-
energy couplet dye (ECD) (clone CD28.2) (BC), apopto-
sis; CD95-FITC (clone DX2) (BDB), regulatory T lym-
phocytes; CD25-ECD (clone B1.49.9) (BC), CD25-FITC
(clone B1.49.9) (Immunotech-BC), CD127-FITC (clone
eBioRDR5) (eBioscience, San Diego, CA, USA) and DC;
HLA-DR- Peridinin-chlorophyll-protein complex (PerCP)-
clone L243 (G46-6), Lineage 1 (CD3, CD14, CD16,
CD19, CD20 and CD56)-FITC, CD11c-PE (clone S-
HCL-3), CD123-PE (clone 9F5) (BDB). Anti-human
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Figure 1 Flow cytometry analysis of periph-
eral blood mononuclear cells. (A)–(C) show
the Treg subsets identified by gating from (A)
CD4+ T cells to (B) CD25+CD127) CD4+ T
cells (quadrant ‘AU4’) and (C) CD25+foxp3+
CD4+ T cells (quadrant ‘AP2’), respectively.
(D)–(F) show the dendritic cell subsets identi-
fied by gating from (D) HLA-DR+ and Line-
age (CD3, CD14, CD16, CD19, CD20 and
CD56) negative PBMC (quadrant H1) to (E)
and (F) for analysis of CD11c- and CD123-
positive cells, respectively.
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used for intracellular staining of foxp3. The cells were
analysed on a Beckman Coulter Cytomics FC 500 MPL
flow cytometry equipped with argon and diode laser for
five-colour detection. Analyses were performed using MXP
version 2.0 (Beckman Coulter, Inc., Brea, CA, USA) flow
cytometry software. A gate was set on the lymphocytes
according to forward and side scatter properties. Statisti-
cal regions were set according to isotype controls. For
foxp3, the statistical marker was set at the upper cut-off
for the CD4-negative population following the manufac-
turer’s instruction. Treg subsets were defined as
CD25+ ⁄ foxp3+ or CD25+ ⁄CD127) CD4+ T cells
(Fig. 1A–C). DC was analysed for the expression of
CD11c and CD123 by gating from HLA-DR+ Lineage
(CD3, CD14, CD16, CD19, CD20 and CD56)-negative
cells (Fig. 1D–F).
Statistical analyses. In a preliminary step, we investi-
gated the data by using histograms and QQ plots for all
cell subsets, and computing the Spearman correlations
between all pairs of cell subsets. This was carried out for
the entire data set and for each patient group. Spearman
correlations were chosen because of their wider range of
detectable relations. Investigating these 12 cell subsets
leads to 66 tests, i.e. we have to take into account multi-
ple effects. Because these tests are not independent, the
Bonferroni level is too conservative. Thus, we used a sig-
nificance level of 0.01.
The research question contains two different types of
comparisons. Comparing the different groups (controls,
LTBI and active TB), we used a two-step test procedure.
First, we used a Kruskal–Wallis test to detect differences
in cell subsets fractions between the groups. In the sec-
ond step, we selected the cell subsets where the Kruskal–
Wallis test detected a significant difference and tested
the groups pairwise using a Wilcoxon test to decide
where the differences detected by the Kruskal–Wallis test
were located. In both cases, we used the Bonferroni sig-
nificance level, i.e. 0.0042 for Kruskal–Wallis test (12
tests) and 0.0167 for the Wilcoxon test (three tests for
each cell subset).
Comparing the pre ⁄post-therapy measurements for the
QFT+ patients, we used a signed rank test, again with a
Bonferroni level of 0.0042. In all investigated cases, we
used non-parametric tests because the preliminary analy-
sis indicated a non-Gaussian distribution at least for
some of the variables. All statistical analyses were per-
formed using Matlab R2010a.
Results
CD4+ CD25+ CD127) T regulatory cells increase in latent and
active TB
There were no significant differences in the percentage of
CD4+ or CD8+ T cells between any of the groups.
Because Treg can be characterized by various immune
markers possibly characterizing different Treg popula-
tions, we analysed both CD4+ CD25+foxp3+ T cells
(Fig. 2A) and CD4+ CD25+CD127) T cells (Fig. 2B).
Both the active TB (P = 0.001) and the LTBI
(P = 0.006) groups demonstrated significantly higher lev-
els of CD127) Treg compared to the control group,
whereas there was no significant difference between the
LTBI and the active TB groups. Likewise, the highest
level of foxp3+ Treg was found in the active TB group,
but for this Treg subset, there were no significant differ-
ences between any of the groups.
T cell activation increase in active, but not in latent TB
T cell activation was evaluated by the expression of the
activation markers CD38, HLA-DR, the co-stimulatory
molecule CD28 and the apoptosis marker CD95 (Fas
receptor) on CD4+ and CD8+ T cells. For both the CD4+
and the CD8+ T cell subsets, the fraction of HLA-
DR+CD38+ cells was higher in the active TB group
compared to both the LTBI (P < 0.01) and the control
(P < 0.001) groups (Fig. 3A,B). Likewise, the expression
of CD28 on CD8+ T cells was significantly lower in the
active TB group compared with both the LTBI
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Figure 2 T regulatory cells. The fraction of
CD4+ T cells expressing (A) CD25+ foxp3+
and (B) CD25+ CD127) in active tuberculo-
sis (TB) (n = 20), latent TB infection before
treatment (LTBI) (n = 20) and controls
(n = 28). The bars represent the means with
95% symmetric confidence intervals. Double
arrows show significant differences between
the respective groups (P < 0.0167).
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(P = 0.014) and control (P = 0.0001) groups, but no sig-
nificant differences were found for the CD4+ T cells
(Fig. 3C,D). We found no significant differences in the
expression of CD95 between any of the groups in any of
the T cell subsets (Fig. 3E,F).
The relationship between T regulatory cells and T cell
activation in TB
The possible association between the various T cell subsets
was studied. When all groups were analysed together, there
was a significant positive correlation between CD127)
Treg and activated CD4+HLA-DR+CD38+ T cells
(P < 0.001, r = 0.4268) (Fig. 4A). This was also found
for the foxp3+ Treg although at a lower level of signifi-
cance (P = 0.0113, r = 0.2689) (Fig. 4B). However,
when the analyses were performed for each study group
separately, the correlation between CD127) Treg and
activated CD4+HLA-DR+CD38+ T cells was maintained
only in the control group. Further, the foxp3+ Treg sub-
set correlated positively with the expression of CD95 on
both CD4+ and CD8+ T cells (P < 0.001, r = 0.4461
and r = 0.4325, respectively) (Fig. 4C,D), but again
when the analyses were performed for each study group
separately, the only correlation that remained was
between foxp3+ Treg and CD95+ CD4+ T cells in the
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Figure 3 T cell activation and apoptosis.
The fraction of CD4+ and CD8+ T cells co-
expressing the activation markers HLA-DR
and CD38 (A and B), the co-stimulatory
molecule CD28 (C and D) and the apoptosis
marker CD95 (E and F) in active tuberculosis
(TB) (n = 20), latent TB infection before
treatment (LTBI) (n = 20) and controls
(n = 28). The bars represent the means with
95% symmetric confidence intervals. Double
arrows show significant differences between
the respective groups (P < 0.0167).
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control group. No overall correlation was found between
CD127) and foxp3+ Treg except in the QFT-negative
control group (P = 0.0014, r = 0.5735).
Myeloid and plasmacytoid dendritic cells in TB
Dendritic cells were phenotyped as CD11c+ mDC or
CD123+ pDC. We found no significant difference in the
proportions of mDC or pDC among PBMC between any
of the groups (Fig. 5).
Effects of preventive therapy on T cell activation and
regulation in latent TB
The percentage of foxp3+ Treg increased in the QFT+
group after preventive anti-TB treatment to a level sig-
nificantly higher than that found before initiation of
therapy (P = 0.0008), whereas no statistical significant
difference was observed for the CD127) Treg subset
(Fig. 6). We found no significant changes in the expres-
sion of activation or apoptosis markers on CD4+ or
CD8+ T cells or in the fractions of the DC subsets.
Because of a low number of subjects converting to
QFT negative after treatment (4 ⁄20), we could not per-
form statistical analyses of possible differences between
converters and subjects who remained QFT positive
(13 ⁄20). However, there seems to be a trend towards
increased expression of HLA-DR and CD38 on CD8+ T
cells in subjects who remained QFT positive indicating
persistent immune activation. The subjects converting to
QFT negative contributed predominantly to the increase
in foxp3+ Treg seen after therapy (data not shown).
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Figure 4 Correlations between T cell sub-
sets. Scatter plots illustrating the correlation
structure for different T cell subsets when all
study groups were analysed together. %
HLA-DR+ CD38+ CD4+ T cells versus (A)
% CD25+CD127-CD4+ T cell and (B) %
CD25+foxp3+CD4+ T cells. % CD25+foxp3+
CD4+ T cells versus (C) % CD95+CD4+ T
cells and (D) % CD95+CD8+ T cells. All
given correlations are Spearman correlations
and the P-values are for the test for vanishing
correlation.
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Figure 5 Myeloid and plasmacytoid den-
dritic cells. The fraction of CD11+ myeloid
dendritic cells (A) and CD123+ plasmacytoid
dendritic (B) cells of peripheral blood mono-
nuclear cells from active tuberculosis (TB)
(n = 20), latent TB infection before treat-
ment (LTBI) (n = 20) and controls (n = 28).
The bars represent the means with 95% sym-
metric confidence intervals.
I. Wergeland et al. Immune Regulation in Tuberculosis 239
..................................................................................................................................................................
 2011 The Authors
Scandinavian Journal of Immunology  2011 Blackwell Publishing Ltd. Scandinavian Journal of Immunology 73, 234–242
Discussion
The role of the various T cell and DC subsets in TB
infection and their contribution to immunopathogenesis
in disease progression has not been clarified. We found
that the level of blood Treg, identified as CD4+CD25+
CD127) T cells, was higher in both the active TB and
the LTBI groups compared to QFT-negative controls. In
contrast, increased T cell activation was predominately
found in the active TB group. The proportions of mDC
and pDC subsets were comparable between the study
groups. After 3 months of preventive anti-tuberculous
therapy, there was an increase in the fraction of foxp3+
Treg in patients with LTBI , but we observed no differ-
ences in the expression of activation or apoptosis markers
on T cells.
Increased levels of T cell activation have been described
in patients with active pulmonary TB and are even more
pronounced in HIV ⁄TB co-infected patients [2, 3].
Consistent with these studies, we found an increased
expression of the activation markers CD38 and HLA-DR
and a corresponding lower expression of the co-stimula-
tory molecule CD28 on CD8+ T cells from patients with
active TB. The level of CD4+ T cell activation was also
increased in patients with active TB. Although large vari-
ations among the subjects in the LTBI group were seen,
our data indicate that immune activation gradually
increases throughout the various stages of TB infection
corresponding to the level of bacterial burden.
There have been few studies of Treg in patients with
LTBI [21]. High levels of circulating Treg have previ-
ously been found in patients with active TB [10–12], but
our data demonstrate that CD127-negative Treg are ele-
vated already from the latent stage of infection. Studies
have shown that CD4+CD25high+foxp3+ Treg cells are
elevated in active TB compared with both uninfected
controls [10] and subjects with LTBI [11, 12]. In another
study, the level of Treg in patients with active TB
decreased after 1 month of anti-tuberculous therapy [13].
In a TB case contact study, the level of foxp3 mRNA
was lower in the TB ELISPOT-positive contacts com-
pared to the TB ELISPOT-negative contacts and both
groups had lower levels than that found in patients with
active TB [22]. In contrast, when we used CD25 and
foxp3 as markers of Treg, we found no significant differ-
ences between the study groups.
It has been suggested that CD127) Treg and foxp3+
Treg possibly represent different populations [9]. In our
study, a correlation between these two Treg subsets was
found only in the control group. In a study of HIV infec-
tion, the positive correlation between foxp3+CD127) and
CD25+CD127) CD4+ T cells found in healthy HIV-nega-
tive subjects was not present in the early chronic stage of
HIV infection [23]. Together these data indicate that dif-
ferent Treg may contribute in various stages of chronic
infections. It has been shown that depletion of
CD4+CD25high and CD4+CD25+foxp3+ cells from
PBMCs from patients with TB, results in increased pro-
duction of IFN-c upon TB stimulation [10, 11, 24], indi-
cating that there is an inverse correlation between Treg
and immune activation. In contrast, although the immu-
nosuppressive function of Treg was not characterized in
our study, we found a positive correlation between the
fractions of Treg and activated CD4+ T cells.
DC can initiate immune responses and stimulate
induction and expansion of Treg [14]. Absolute numbers
of DC have been shown to decrease in patients with TB
compared to healthy controls [17]. Still, although the
numbers of pDC and mDC were not estimated, in our
study, we did not find any differences in the fraction of
DC subsets among the various groups or any correlation
between DC and Treg subsets.
Altogether, these data suggest that different Treg sub-
sets may have different capability to regulate immune
activation and that modulation may be induced by differ-
ent signals in the various stages of TB infection. As we
found gradually higher fractions of CD127) Treg
throughout the various stages of TB infection correlating
to immune activation, a possible theory is that higher
bacterial burden and inflammation stimulate to increased
levels of Treg to balance between anti-TB T cell
responses and immune-mediated pathology. In support of
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Figure 6 T regulatory subsets before and
after preventive anti-tuberculous treatment.
The fraction of CD25+foxp3+ (A) and
CD25+CD127) Treg (B) in LTBI before
(LTBI ⁄ pre) and after (LTBI ⁄ post) 3 months
of prophylactic anti-tuberculous treatment.
The bars represent the means with 95% sym-
metric confidence intervals. Double arrows
show significant differences between the
respective groups (P < 0.0167).
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this, in a study of macaques, there were increased fre-
quencies of Treg cells in blood as the animals developed
disease [25]. An alternative explanation may be that Treg
inhibit protective Th1 responses facilitating mycobacte-
rial replication and act as a causative factor in the pro-
gression to active disease [12]. We found an increase in
foxp3+ Treg after preventive anti-TB treatment. Our very
limited data demonstrate that this was most dominant in
patients converting to QFT negative and with reduced
CD8+ T cell activation after treatment, possibly indicat-
ing that expansion of this Treg subset contributes to sup-
pression or eradication of TB.
Apoptosis of TB reactive T cells may account for the
depression of TB-induced T cell responses seen in active
TB, but data are conflicting [3, 26]. CD95 (Fas receptor),
which upon ligation with Fas ligand induces an apoptotic
death signal, was expressed by a higher proportion of
CD8+ T cells and a lower proportion of CD4+ T cells in
patients with pulmonary TB [3]. To our knowledge, no
such studies have been performed in patients with LTBI.
In our study, we could not demonstrate any differences
in the expression of CD95 on T cells in the various study
groups, but there was a positive correlation between
foxp3+ Treg and the expression of CD95 on both CD4+
and CD8 T cells.
In this study, patients with no signs of active TB
based on X-ray and clinical evaluation, and with a posi-
tive QFT test, were assumed having LTBI. The QFT test
is more specific in the diagnosis of LTBI than the TST
and at a 90% certainty threshold LTBI is best diagnosed
by the QFT test in immunocompetent persons [27]. The
TST-positive ⁄QFT-negative subjects in our study con-
sisted predominately of ethnic Norwegians with little
risk of TB infection [20]. They are probably not TB
infected and believed to have false-positive TST because
of previous BCG vaccination.
There are some limitations of our study. First,
immune responses specific to TB were not evaluated. Our
findings may therefore be influenced by immune activa-
tion mediated by other stimuli than TB. However, both
the LTBI and the control groups were all healthy at
inclusion. Second, we had no samples available for analy-
ses from the active TB group after therapy, where, due to
higher bacterial burden, we would expect larger effects
on T cell subsets in response to treatment. Third, as
often carried out in such studies because of logistics, flow
cytometry analyses were performed on cryopreserved
PBMCs possibly affecting the results. To minimize this
problem, the lymphocyte gate was set according to for-
ward and side scatter properties excluding dead cells.
Finally, we have studied cells from peripheral blood
rather than from the disease compartment itself. Studies
were clinical samples from disease sites have been com-
pared with time matched blood samples indicate that
results from peripheral blood give an attenuated picture
of events at the disease site [10, 24]. In macaques studies,
it has also been shown that right after infection the fre-
quency of Treg cells in peripheral blood rapidly decreased
whereas they increased in the airways [25]. Still, we
believe our results are valid because we have demon-
strated differences between the TB groups and controls
that could be explained by biological mechanisms.
In conclusion, there seems to be an increased level of
immune activation including interactions of different
Treg subsets in active and LTBI still present at the end
of preventive therapy. The results indicate that different
Treg subsets may have different functions and that the
degree of bacterial burden and immune activation is asso-
ciated with the level of CD127) Treg in patients with
TB infection.
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12 Marin ND, Parı́s SC, Vélez VM, Rojas CA, Rojas M, Garcı́a LF.
Regulatory T cell frequency and modulation of IFN-gamma and
IL-17 in active and latent tuberculosis. Tuberculosis (Edinb)
2010;90:252–61.
13 He XY, Xiao L, Chen HB et al. T regulatory cells and Th1 ⁄Th2
cytokines in peripheral blood from tuberculosis patients. Eur J Clin
Microbiol Infect Dis 2010;29:643–50.
14 Yamazaki S, Steinman RM. Dendritic cells as controllers of
antigen-specific Foxp3+ regulatory T-cells. J Dermatol Sci 2009;54:
69–75.
15 Henderson RA, Watkins SC, Flynn JL. Activation of human den-
dritic cells following infection with Mycobacterium tuberculosis.
J Immunol 1997;2:635–43.
16 Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic
cells. Annu Rev Immunol 2000;18:767–811.
17 Lichtner M, Rossi R, Mengoni F et al. Circulating dendritic cells
and interferon-alpha production in patients with tuberculosis: corre-
lation with clinical outcome and treatment response. Clin Exp
Immunol 2006;143:329–37.
18 Pai M, Zwerling A, Menzies D. Systematic review: T cell-based
assays for the diagnosis of latent tuberculosis infection: an update.
Ann Intern Med 2008;3:177–84.
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Summary Objectives: Biomarkers for diagnosis and therapy efficacy in tuberculosis (TB)
are requested. We have studied biomarkers that may differentiate between active and
latent TB infection (LTBI), the influence of HIV infection and changes during anti-TB chemo-
therapy.
Methods: Thirty-eight plasma cytokines, assessed by multiplex and enzyme immunoassays,
were analyzed in patients with active TB before and during 24 weeks of anti-TB chemo-
therapy (n Z 65), from individuals with LTBI (n Z 34) and from QuantiFERON-TB (QFT) nega-
tive controls (n Z 65). The study participants were grouped according to HIV status.
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Results: Plasma levels of the CXC chemokine IP-10 and soluble TNF receptor type 2 (sTNFr2)
significantly differentiated active TB from the LTBI group, irrespective of HIV status. In the
HIV-infected group the sensitivity and specificity was 100% for IP-10 with a cut-off of
2547 pg/mL. Plasma IP-10 declined gradually during anti-TB chemotherapy (12e24 weeks,
p Z 0.002) to a level comparable to LTBI and QFT negative control groups. sTNFr2 fluctuated
throughout therapy, but was decreased after 12e24 weeks (p Z 0.006).
Conclusions: IP-10 distinguished with high accuracy active TB from LTBI irrespective of HIV
infection and declined during anti-TB chemotherapy. Plasma IP-10 may serve as a diagnostic
biomarker to differentiate between the stages of TB infection and for monitoring therapy ef-
ficacy.
ª 2015 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Association. This is an open access article under the CC BY-NC-SA license (http://
creativecommons.org/licenses/by-nc-sa/4.0/).
Introduction
Tuberculosis (TB) is a major global health problem, espe-
cially in the developing world. The World Health Organiza-
tion estimates that one third of the world’s population has
latent TB infection (LTBI), and that there were 9.0 million
incident active TB cases and 1.5 million deaths caused by
TB in 2013.1 Human immunodeficiency virus (HIV) infection
is globally the major risk factor contributing to the resur-
gence of TB,2 and the emergence of multi- and extensively
drug resistant (MDR and XDR) strains of Mycobacterium
tuberculosis (Mtb) have further aggravated the situation.1
Strategies for TB control aim to reduce transmission by
identification and treatment of infectious cases as well as
to reduce development of active disease by offering pre-
ventive therapy to individuals with LTBI. However, there is
shortage of reliable and rapid diagnostic tools that can
identify and discriminate between latent and active TB,
and predict therapy responses.3,4 The currently available
tests for diagnosing LTBI are the century old tuberculin
skin test (TST) and the more recent interferon gamma
(IFN-g)-release assays (IGRAs). The IGRAs offer better spec-
ificity compared to the TST, but both tests have suboptimal
sensitivity in HIV co-infected individuals, and cannot distin-
guish between the various stages of TB infection or be used
for evaluation of treatment efficacy.3,5 Sputum culture con-
version within the first 2 months of anti-TB chemotherapy
could serve as a predictor of a favorable outcome,6,7 but
may also fail as predictive marker of cure in individual pa-
tients,8,9 and are not applicable in extra-pulmonary and
culture negative TB infection. Further, the need of alterna-
tive tools for monitoring treatment efficacy and for identi-
fying patients at high risk of relapse is emphasized by the
challenges of MDR- and XDR-TB cases, which require long
lasting treatment with potentially inefficient and toxic
drugs. Tools for monitoring treatment are also essential
for accelerating drug development.
Alternative biomarkers have been sought to improve
immune diagnosis of TB and monitoring of treatment
efficacy. Various single or combinations of markers have
been suggested to differentiate between latent and active
TB infection.10e15 However, a recent review concludes that
there is no clear pattern of markers able to differentiate
between the various TB infection stages.16 Tests based on
IFN-g -inducible Protein 10 (IP-10)/CXCL10, one of the
most studied surrogate biomarkers, perform comparably
to the QuantiFERON-TB (QFT) in most patient groups,17
but may increase the diagnostic accuracy of TB infection
in both HIV-infected individuals18e20 and children.21e24 It
has also been suggested that IP-10 can be used to monitor
treatment efficacy,14,25e29 but longitudinal studies per-
formed on diverse patient populations are limited.
The aims of this study were to examine the potential of
38 selected cytokines, including interleukins, chemokines
and growth factors to differentiate between the stages of
TB infection as well examine the influence of HIV co-
infection and the changes in these markers during anti-TB
chemotherapy. Plasma IP-10 appeared to be the most
consistent of the biomarkers studied, as it was the only
marker that significantly differentiated active TB from both
the LTBI and QFT negative control groups irrespective of
HIV status and also gradually and significantly declined
during anti-TB chemotherapy.
Materials and methods
Study participants and sample collection
The study population was included from clinical studies
performed at three different hospitals in Norway in the
period 2006e2012; Haukeland University Hospital,30,31
University Hospital of Northern Norway31 and Oslo Univer-
sity Hospital.32 The study participants were recruited
from patients diagnosed with active TB and from individuals
referred to the hospitals for medical evaluation of LTBI
based on a positive TST and/or exposure of TB.30,32 HIV-
infected individuals were recruited from outpatient infec-
tious disease clinics.31 QFT negative/HIV-uninfected indi-
viduals from age-matched employees with no known
exposure to TB served as controls.
Thoracic X-ray and clinical examination were performed
in all participants and an induced sputum sample and/or
biopsy was obtained for acid fast staining and culture by
BACTEC 960 MGIT liquid culture media (BD) or Lövenstein
Jensen solid media. The patients diagnosed with active TB
were given standard anti-TB chemotherapy according to
national guidelines.33 Subjects with a positive QFT, but no
clinical signs or symptoms of active TB and no prior TB
that could explain QFT positivity, were defined as LTBI.
Blood samples were obtained before start of any anti-TB
chemotherapy and drawn into EDTA tubes. Plasma was
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harvested after centrifugation, snap-frozen and stored at
80 C until analysis. Plasma samples from patients with
active TB were also obtained at 2e4 weeks, 6e12 weeks
and 12e24 weeks after the start of anti-TB chemotherapy.
Written informed consent was obtained from all partic-
ipants. The study was approved by the respective Regional
Committees for Ethics in Medical Research (REK-Vest, REK-
Nord and REK-Sør-øst).
QuantiFERON-TB Gold In-tube assay
The QuantiFERON TB-Gold In-tube assay was performed
according to the manufacturer’s instructions (Cellestis
Ltd, Qiagen, Chadstone, VIC, Australia) at the respective
hospitals. The cut-off value for positive test was
0.35 IU/ml.
Multiplex cytokine analysis
Plasma samples were analyzed using a multiplex cytokine
assay (Bio-Plex Human Cytokine 27-Plex Panel; Bio-Rad
Laboratories Inc., Hercules, CA) containing assays for
interleukin (IL)-1b, IL-1 receptor antagonist (IL-1ra), IL-2,
IL-4, IL-5, IL-6, IL-7, IL-8/CXCL8, IL-9, IL-10, IL-12(p70), IL-
13, IL-15, IL-17, basic fibroblast growth factor (bFGF),
granulocyte colony stimulating factor (G-CSF), granulocyte
macrophage colony stimulating factor (GM-CSF), IFN-g,
eotaxin/CCL11, IP-10/CXCL10, macrophage chemotattrac-
tant protein 1 (MCP-1)/CCL2, macrophage inflammatory
protein 1 alpha (MIP-1a)/CCL3, MIP-1b/CCL4, regulated on
activation, normal T cell expressed and secreted (RANTES)/
CCL5, tumor necrosis factor (TNF), platelet-derived growth
factor -BB (PDGF-BB) and vascular endothelial growth
factor (VEGF).
The samples were analyzed on a Multiplex Analyser using
Bio-Plex Manager 6.0 (Bio-Rad Laboratories) according to
the manufacturer’s instructions. Intra- and inter-assay
coefficients of variation were <12% for all analytes. Nine
of the markers evaluated (IL-1b, IL-2, IL-4, IL-5, IL-9, IL-10,
IL-13, IL-15 and GM-CSF) were below the lower detection
level (LDL) or detected at very low levels in all samples
(>80% below the LDL of the assay), and were therefore
excluded from further statistical analysis. The remaining
occasional values (<20%) below the LDL were replaced by a
defined common value below the LDL (0.001), which
allowed non-parametric statistical analysis.
Enzyme immunoassays (EIA)
Plasma levels of CXCL16, pentraxin 3 (PTX3), soluble TNF
receptor 2 (sTNFr2), Fas Ligand (FasL), thymus and activa-
tion regulated chemokine (TARC)/CCL17), osteoprotegerin
(OPG), activated leukocyte cell adhesion molecule (AL-
CAM), IL-23, secreted frizzled-related protein 3 (sFRP3) and
C-reactive protein (CRP) were measured by EIAs (R&D
Systems, Stillwater, MN). Intra-and inter-assay coefficients
of variation were <10% for all except FasL (<15%). MD-2
was analyzed by an in-house ELISA as previously
described.34 Briefly, MD-2 was captured on immune plates
coated with a TLR-4-Fc fusion protein and detected with di-
goxygenin labelled MD-2 mAb 5D7 or digoxigenin labelled
IIC1 and anti-digoxygenin-HRP (Roche). The MD-2 standard
was purchased from R&D Systems, Stillwater, MN.
Statistical analysis
All statistical analyses were performed using IBM SPSS
statistics 21, Matlab 7.10. or GraphPad Prism 6. We initially
analyzed the HIV-infected and HIV-uninfected TB groups
separately using ManneWhitney U-test to detect pairwise
differences between the study subgroups at baseline. In
addition, we applied a binary logistic regression model to
evaluate whether each of the markers was able to differ-
entiate between active, LTBI and QFT negative controls
pairwise, when adjusted for age, sex and HIV-status.
ManneWhitney U-test was used to compare HIV-
uninfected MDR-Mtb vs. drug sensitive Mtb, and extrapul-
monary vs. pulmonary active TB cases, at time points where
the sample size in each of these groups were n  5. Wil-
coxon signed rank test was used to evaluate changes in
the levels of markers in patients with active TB from base-
line to each follow up time point during anti-TB chemo-
therapy. Spearman’s correlations were used to detect
relationships between the CD4 counts and selected markers
in the HIV-infected group.
The general significance level was set to 0.05. Taking
into account effects of multiple testing, the Bonferroni
adjustment would be too conservative due to the depen-
dence between the markers. Thus, we decided to use a
marginal significance level of 0.005 (corresponding to
Bonferroni adjustment for 10 tests), and to describe results
with p-values equal to or above 0.005 as significant and less
than 0.05 (0.005  p < 0.05) as tendencies.
Receiver operator characteristic (ROC) curve analyses
were performed for the most promising marker differenti-
ating between active and LTBI based on the results of the
aforementioned tests. The optimal cut-off levels were




A total of 164 study participants had plasma samples avail-
able for analysis and these were classified into three groups;
1) Active TB (n Z 65), 2) QFT-positive LTBI (n Z 34) and 3)
QFT negative controls (n Z 65). The patients were further
grouped according to HIV status. The clinical characteristics
of the study participants are summarized in Table 1. Six
(9.2%) of the patients with active TB, 23 (67.6%) of the indi-
viduals with LTBI and 52 (80.0%) of the QFT negative controls
were HIV-infected. A total of 51 (63%) of the HIV patients
were treated with antiretroviral therapy at inclusion in the
study. Two of the QFT negative HIV-infected controls had ac-
quired immune deficiency syndrome (AIDS)-defining infec-
tions (Herpes simplex virus, Mycobacterium avium
complex, Varicella zoster virus), with high HIV viral load
and CD4 counts below 100, but with no clinical signs of TB.
AIDS-defining infections were not seen in the LTBI group.
The active TB diagnosis was based on positive Mtb cul-
ture in 60 of the patients, whereas in five patients the
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diagnosis was based on clinical evaluation and character-
istic histopathological or radiological findings. There were
11 MDR-TB cases and two patients with disseminated TB
disease.
The patients with active TB had plasma samples ob-
tained at 2e4 weeks (n Z 24), at 6e12 weeks (n Z 24) and
at 12e24 weeks (n Z 20). Only two HIV-infected patients
with active TB had available plasma samples during treat-
ment, and these were therefore excluded from the statis-
tical analyses. All the patients with plasma samples
available during treatment were successfully treated,
except one patient who developed concomitant serious
disease with intestinal perforation and septicaemia leading
to death after 8 weeks of therapy. Thus, this patient was
excluded from the follow-up analyses.
Impact of HIV infection on cytokine levels in
various stages of TB infection
We found significant higher levels of IP-10 and eotaxin
(p < 0.005) and a tendency of higher levels of FasL and
sTNFr2 (0.005  p < 0.05) in HIV co-infected compared with
HIV-uninfected active TB cases (Figs. 1 and 2). In contrast,
there was no significant impact of HIV infection on the
levels of any of the markers neither in subjects with LTBI
nor in QFT negative controls, although a tendency of
increased IP-10 and CXCL16 levels (0.005  p < 0.05)
were seen in the HIV-infected compared to the HIV-
uninfected LTBI group. Among QFT negative controls a ten-
dency of decreased level of MIP-1a, MIP-1b, sFRP3
(0.005  p < 0.05) and increased level of OPG
(0.005  p < 0.05) were observed in HIV-infected compared
with HIV-uninfected individuals.
We further analyzed whether there were any correla-
tions between the CD4 count and the level of IP-10 and
eotaxin, respectively, in the HIV-infected individuals. We
found a significant negative correlation between the CD4
count and the level of IP-10 (p < 0.005, r Z 0.349)
(Fig. 3), but not with eotaxin (p Z 0.098, r Z 0.185).
Cytokines differentiating between the various
stages of TB infection
Since we observed a significant impact of HIV co-infection
on the pattern of biomarkers in patients with active TB we
analyzed the HIV-infected and HIV-uninfected TB groups
separately.
In HIV-infected individuals there were significantly
higher levels of IP-10 and sTNFr2 in the active TB group
compared with both the LTBI group and QFT negative
controls (p < 0.005, Fig. 2), and there was a tendency of
PTX3, eotaxin and MCP-1 differentiating between active
and LTBI (0.005  p < 0.05). In contrast, in HIV-
uninfected individuals, PTX3 was the only marker that
significantly differentiated between active and LTBI
(p < 0.005, Fig. 2), but in addition IP-10, IL-8, VEGF, MD-2
and sFRP3 showed a tendency of differentiating
(0.005  p < 0.05). However, several markers significantly
distinguished (IL-8, PDGF-BB, TARC and CRP, p < 0.005) or
tended to distinguish (sFRP3, IL-7, eotaxin, OPG and
CXCL16, 0.005  p < 0.05) active TB from QFT negative
controls.
IP-10 and sTNFr2 also differentiated significantly
(p < 0.005) between active TB and both LTBI and QFT
negative controls when a binary logistic regression model
adjusting for HIV status, age and gender was applied. In
addition, in this model, PTX3 and CRP significantly differ-
entiated between active TB and QFT negative controls
(p < 0.005), and tended to differentiate between active TB
and LTBI (0.005  p < 0.05).
The diagnostic accuracy of IP-10 in differentiating be-
tween active TB, LTBI and the QFT negative control group
was investigated by ROC curve analyses (Table 2). In HIV-
infected individuals a cut-off level of 2547 pg/mL
Table 1 Characteristics of the study participants.













Median age (range) 46 (38e64) 30 (16e91) 38 (21e48) 44 (24e61) 37 (19e68) 36 (26e70)
Sex: males/females 4/2 29/30 13/10 4/7 24/28 5/8
Origin: TB high/low
endemic country
5/1 52/7 23/0 8/3 34/18 1/12
Median CD4 count
(cells/mL, range)
286 (50e425) ND 475 (110e1870) ND 394 (3e1270) ND
HIV patients on
antiretroviral therapy (%)








a 5 QFT-negative/HIV-uninfected controls were included in the Multiplex bead assay. 13 QFT-negative/HIV-uninfected controls were
included in the ELISA assays. ND: Not determined/relevant.
b Monoresistance against isoniazid, streptomycin or pyrazinamide.
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Figure 1 Comparisons of cytokine levels between patients with active TB, latent TB and QFT-negative controls and between HIV-
infected and HIV-uninfected patients (ManneWhitney U test). Significant p-values (p < 0.005) are shown as a colour scale in green,
and p-values described as tendencies (0.005  p < 0.05) are shown as a colour scale ranging from red to black. ATB: active TB
infection. LTBI: Latent TB infection. QFT-: QuantiFERON-TB negative controls.
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discriminated active TB from LTBI with 100% sensitivity and
specificity, whereas in HIV-uninfected individuals the
optimal cut-off level was 689 pg/mL, and the sensitivities
and specificities were 71% and 82%, respectively.
Changes in cytokine levels during anti-TB
chemotherapy
In HIV-uninfected patients with active TB, we analyzed the
levels of the various markers at different time-points
throughout therapy. The level of IP-10 decreased gradually
during treatment. There was a tendency of decrease
observed already after 6e12 weeks (p Z 0.022, Fig. 4).
However, the decrease was significant first after 12e24
weeks (p Z 0.002), and the level was then comparable to
that seen both among the LTBI and in the QFT negative con-
trol group. By using the optimal cut-off level of 674 pg/mL
for differentiation between active TB and non-TB in HIV-
uninfected patients, 43/59 (73%) of the active TB patients
scored positive for plasma IP-10 at baseline, whereas 9/20
(45%) were positive at week 12e24. Only one patient with
extrapulmonary TB scored negative at baseline and became
positive during treatment. However, this patient had IP-10
levels close to cut-off both at baseline and during therapy.
sTNFr2 tended to decrease to the level of LTBI cases and
QFT negative controls after 12e24 weeks of treatment
(p Z 0.006), but in contrast to IP-10, which showed a uni-
form decrease over time, the level of sTNFr2 fluctuated
(Fig. 4).
Figure 2 Plasma levels of IP-10, sTNFr2, PTX3 and eotaxin in HIV-infected and HIV- uninfected patients with active TB, latent TB
and in QFT negative controls. The boxes show the median and interquartile range, and the whiskers show minimum and maximum
values. Statistical analysis was performed using the ManneWhitney U test. Brackets represent statistically significant differences
(p < 0.005).
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Several of the other markers that significantly differen-
tiated between active TB and the LTBI and/or the QFT
negative control groups at baseline also declined
throughout therapy. PDGF-BB and TARC were significantly
decreased already after 2e4 weeks (p Z 0.002 and
p Z 0.004 respectively, Fig. 4), and there was a tendency
of decrease in CRP and IL-8, which reached the significance
level at week 12e24 (p Z 0.005, Fig. 4). PTX3, that signif-
icantly differentiated between active and LTBI at baseline,
did not decline during treatment. In contrast, a tendency of
increasing concentration of PTX3 was found after 6e12
weeks of treatment (p Z 0.042). However, when changes
in biomarker levels were analyzed in the Mtb sensitive
group separately, we found that the level of PTX3 tended
to decrease at week 6e12 (p Z 0.013), whereas there
was an increase in PTX3 for the majority of the MDR TB pa-
tients in the same period. For the other markers analyzed
we found no distinct differences in response patterns
when studying the drug sensitive Mtb cases separately
versus all active TB cases taken together.
There were also several markers which did not discrim-
inate significantly between the various study groups at
baseline, but where a significant decrease in concentra-
tions were observed in active TB cases during treatment;
RANTES (2e4 weeks), IL-1ra, IL-6, IL-12(p70), bFGF, IFN-g,
MIP-1a, TNF and VEGF (6e12 weeks), and G-CSF, MD-2 and
IL-7 (12e24 weeks), p < 0.005, Fig. 4).
Discussion
In this study we have examined the potential of plasma
cytokines to differentiate between active and LTBI in HIV-
infected and HIV-uninfected individuals and longitudinal
changes in these markers during anti-TB chemotherapy. For
the first time we document that IP-10 and sTNFr2 can
differentiate active TB cases from both individuals with
LTBI and QFT negative controls irrespective of HIV status,
age and gender. Moreover, we found that the level of IP-10
in HIV-uninfected active TB cases decreased gradually to
the same level as LTBI and QFT negative controls after
12e24 weeks of anti-TB chemotherapy.
IP-10 is a chemokine produced by antigen presenting
cells mainly in response to IFN-g and TNF. It has been shown
that plasma levels of IP-10 are increased in bacteremia35
and infections with hepatitis C virus,36 HIV37,38 and
TB,14,25 and appear to correlate with the extent of inflam-
mation. In our study, the level of IP-10 was significantly
higher in HIV co-infected active TB cases compared with
HIV-uninfected cases. This is in concordance with a study
by Juffermans et al.,39 but in contrast, Mihret et al.14,27
and Riou et al.28 found no significant differences in the
level of IP-10 with respect to HIV-infection in patients
with active TB before anti-TB chemotherapy. We found a
significant negative correlation between the CD4 count
and the level of IP-10 in HIV-infected individuals supporting
studies of HIV-infected individuals without TB co-infec-
tion.37,40 The discordant results could therefore be due to
differences in CD4 counts between the HIV-infected groups
in the various studies.
IP-10 circulates at much higher levels compared to IFN-g
and has been extensively studied as an alternative to IFN-g
for immunodiagnosis of TB.16,17 In agreement with our re-
sults, it has been shown that plasma levels of IP-10 are
elevated in active TB cases compared with household con-
tacts.14,25,41 Our study is a valuable contribution to the
literature since HIV-infected subgroups are included both
in the active TB, the LTBI and the QFT negative groups,
Figure 3 Negative correlation between CD4 counts and
plasma IP-10 levels in HIV-infection. Spearman’s correlations
were used to detect relationships between the CD4 counts
and selected markers in the HIV-infected group. There was a
significant negative correlation between the CD4 count
(cells/mL) and the plasma level of IP-10 (pg/mL) in HIV infected
individuals (p < 0.005, r Z 0.349). ATB: active TB infection.
LTBI: Latent TB infection. QFT-: QuantiFERON-TB negative
controls.




Sensitivity (95% CI) Specificity (95% CI) AUC (95% CI) p-value
HIV infected ATB vs. LTBI 2547 100 (54.1e100) 100 (85.2e100) 1.00 (1.00e1.00) <0.001
ATB vs. QFT negative 2532 100 (54.1e100) 92.3 (81.5e97.9) 0.96 (0.91e1.00) <0.001
HIV uninfected ATB vs. LTBI 689 71.2 (57.9e82.2) 81.8 (48.2e97.7) 0.74 (0.59e0.89) 0.012
ATB vs. QFT negative 674 72.9 (59.7e83.6) 60.0 (14.7e94.7) 0.66 (0.52e0.80) 0.235
ATB: Active TB infection. LTBI: Latent TB infection. QFT: QuantiFERON-TB. AUC: Area under the ROC curve. 95% CI: 95% confidence
interval.
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and we demonstrate that the plasma level of IP-10 distin-
guish active TB from LTBI and QFT negative controls irre-
spective of HIV co-infection. The ROC curve analyses
show that plasma IP-10 with a cut of 2547 pg/mL clearly dif-
ferentiates between active TB and LTBI in HIV-infected in-
dividuals with 100% sensitivity and specificity. In HIV-
uninfected individuals the diagnostic accuracy was less
optimal and the cut-off level was 689 pg/mL which is
notably higher than reported by Hong et al. (119.5 pg/
mL).41 This discrepancy is most likely explained by differ-
ences in methods of detection and variations in study pop-
ulations, and emphasizes the importance of determining
validated cut-offs before IP-10 can be used in clinical
practice.
Our results support previous studies demonstrating a
decrease in plasma level of IP-10 upon anti-TB chemo-
therapy of HIV-uninfected active TB cases,14,25e28 whereas
there are conflicting results in HIV co-infected cases. Riou
et al. reported that IP-10 decreased irrespective of HIV
infection,28 but Mihret et al. documented a decline only
for HIV-uninfected cases.27 In a study by Azzuri et al., IP-
10 increased in household contacts during progression to
active TB and during relapse of TB in patients who previ-
ously had completed anti-TB chemotherapy.25 Patients
with active TB with moderate to high risk of relapse decline
less in IP-10 during treatment compared with low risk pa-
tients.26 It has also been suggested that serial determina-
tions of serum IP-10 can be used to identify individuals
with rheumatoid arthritis at high risk of developing active
TB during TNF inhibitor treatment.42 Further, plasma level
of IP-10 correlates with the sputum smear acid fast bacilli
grade26,43 and the degree of lung involvement.25 Although
there was a tendency of decline already at 6e12 weeks,
we found defined by our definition of significance level, a
decrease in the level of IP-10 first after 12e24 weeks of
treatment. We report a reduction in the fraction of active
Figure 4 Plasma levels of selected soluble markers during anti-TB chemotherapy; IP-10, sTNFr2, CRP, PDGF-BB, IFN-g and TNF-a
in HIV-uninfected patients with active TB before and after 2e4, 6e12 and 12e24 weeks compared to the HIV-uninfected LTBI and
QFT-negative groups. Changes in the plasma level of markers from baseline to each follow up time point during treatment were
analyzed using Wilcoxon matched pairs signed rank test. Brackets represent statistically significant differences (p < 0.005).
ATB: active TB infection. LTBI: Latent TB infection. QFT-: QuantiFERON-TB negative controls. BL: baseline.
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TB patients with positive plasma IP-10 from 73% at baseline
to 45% during anti-TB chemotherapy in line with a previous
report.26 Other markers, including PDGF-BB, TARC and IFN-
g showed an earlier significant decrease in response to
therapy compared with IP-10, but these markers were not
able to differentiate between the various stages of TB
infection.
IP-10 measured directly in plasma is unspecific for TB,
but IP-10 has also been studied as a potential readout
biomarker in in vitro Mtb specific immunoassays. A review
by Ruhwald et al. concludes that IP-10 release assays
perform comparably to the QFT-test in most patient groups,
but may improve the diagnostic accuracy in children and in
HIV-infected individuals with low CD4 counts.17 However,
the Mtb specific immunoassays does not seem to be able
to differentiate between active and LTBI,3,17 and IGRAs
cannot be used for monitoring treatment.5 Hong et al.
found that IP-10 secretion in response to QFT antigens
decreased during anti-TB chemotherapy,26 whereas Kabeer
et al. could not confirm this, but rather detected decrease
in response to RD1-selected peptides.29
The relatively high level of plasma IP-10 compared with
other biomarkers, allows for simplification of analyzes.
Methods for quantification of IP-10 in dried blood and
plasma spots (DBS/DPS) have been developed, facilitating
point-of-care tests and transport of samples at ambient
temperatures.44e46 DPS/DBS-based IP-10 release assays
offer comparable diagnostic accuracy to the QFT.44,47 IP-
10, in contrast to IFN-g and TNF-a, could also be detected
in urine from TB patients and pulmonary TB patients have
significantly higher urine IP-10 levels than healthy con-
trols.48 Moreover, the urine IP-10 level in cured TB patients
were comparable to that found in healthy controls.48 Urine
samples have several advantaged including non-invasive
collection, low cost and no need of special equipment or
personnel. Still, care most be taken when detecting IP-10
in urine, as high urine IP-10 levels are also associated
with chronic hepatitis C virus infection.49 Thus, further
studies are needed to determine whether urine IP-10 is a
reliable alternative to plasma IP-10.
sTNFr2 can act as a TNF antagonist by competing with
the cell membrane receptors for cytokine binding. It is the
biologically active component of the TNF inhibitor etaner-
cept, which, among other TNF inhibitors, has been associ-
ated with increased risk of reactivation of latent TB
infection.50 Elevated levels of TNF have been found in
patients with active TB compared with household contacts
and healthy controls.51 Further, Jufferman et al. found that
both sTNFr1 and sTNFr2 are increased in active TB cases
and decline during treatment.52 In our study, although
finally declined, the level fluctuated during treatment.
Riou et al. show that the level of TNF also fluctuates during
treatment.28 We found a gradual decrease in the level of
TNF, which was significant after 6e12 weeks of therapy.
However, since there were no significant differences in
TNF level between any of our study groups at baseline
this questions the usefulness as biomarker for therapy effi-
cacy. Finally, if sTNFr2 may serve as a reliable marker of
TNF activity is also unknown.
The pentraxin family, including CRP and PTX3, is
involved in the acute phase reaction to inflammation.53
PTX3 was the only marker that significantly differentiated
between active and LTBI when HIV-uninfected individuals
were studied separately, and also showed a tendency of
differentiating between these groups in HIV-infected indi-
viduals. Azzuri et al. found that the plasma level of PTX3
was higher in patients with active TB compared with
healthy household controls, decreased with successful
treatment and increased in patients with treatment fail-
ure.25 When patients with MDR-TB and drug sensitive Mtb
were analyzed as one group we found a tendency of in-
crease in the level of PTX3 during treatment. However,
when analyzed separately, PTX3 tended to decrease in
the drug sensitive Mtb group whereas there was an initial
increase, followed by a decline after 24e48 months in
MDR TB patients (data not shown). This may indicate that
there is a delayed response to treatment in MDR compared
with drug sensitive Mtb. CRP, which is extensively used as a
marker of inflammation, declined steadily, but only near
significantly, during treatment.
The main limitations of our study are the low sample size
of HIV-infected patients with active TB and the lack of
longitudinal follow up plasma samples from this group
during treatment. This was included in the design of the
original study,31 but there was a low prevalence of active
TB in the HIV-infected population, and only two HIV-
infected patients had plasma samples obtained during
treatment. Also, the changes in markers during treatment
of active TB were assessed together regardless of drug
resistant or sensitive Mtb, although the treatment differed
in composition of antibiotics and length. We found indica-
tions that the kinetics of some of the biomarkers may differ
between MDR and drug sensitive Mtb. Still, the majority of
patients had Mtb sensitive strains, received standard anti-
TB chemotherapy and all patients responded to treatment.
Finally, since plasma IP-10 is unspecific for TB, our study
should also have included patients with diagnoses other
than TB, including AIDS-defining infections, to optimally
validate the accuracy of the method. The two HIV patients
in the QFT negative control group with other opportunistic
infections clearly demonstrate this since they had plasma
IP-10 levels above the median level of the HIV-infected
active TB group. Still, our study was not designed to fully
validate IP-10, but we recommend awareness of infections
other than TB in the interpretation of plasma levels of IP-
10, particularly in patients with HIV-confection.
In conclusion, IP-10 appears to be the most consistent of
the biomarkers studied as it was the only marker that
significantly differentiated active TB from both LTBI and
QFT negative controls irrespective of HIV status, and also
significantly declined during anti-TB chemotherapy of HIV-
uninfected active TB cases. Although not specific for TB,
plasma level of IP-10 may give information about the stage
of infection, and may also be used to monitor the effect of
treatment, but further studies are needed to validate and
standardize IP-10 assays.
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Erratum 
In the paper “Wergeland I, Pullar N, Assmuss J, Ueland T, Tonby K, Feruglio S, 
Kvale D, Damås JK, Aukrust P, Mollnes TE, Dyrhol-Riise AM. IP-10 differentiates 
between active and latent tuberculosis irrespective of HIV status and declines during 
therapy. J Infect. 2015 Apr;70(4):381-91.”  there are errors in figure 1 and 2.  
In Fig 1, it is incorrectly shown that there is a significant difference in the level of IL-
1ra between HIV+ vs HIV- individuals, illustrated by a green box in the upper left 
corner of the figure. In the attached Fig 1 this is corrected to show that there is no 
significant difference and that the p-value is above 0.05, illustrated by a white 
coloured box. 
In Fig 2, the unit on the y-axis of the graphs showing IP-10, sTNFr2 and Eotaxin is 
wrong. In the attached Fig 2 the unit is corrected to pg/mL for IP-10 and Eotaxin and 
to ng/mL for sTNFr2.  
We apologize for the errors. The erratum has been sent to the Journal of Infection, but 
is not yet published. 
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Interferon gamma release assays (IGRAs) do not discriminate between active tuberculosis
(TB) and latent TB infection (LTBI), which limit their use in TB endemic areas. Subjects with
QuantiFERON-TB (QFT) results around the diagnostic cut-off more likely show inconsis-
tent results on serial testing which makes the interpretation of the assay difficult. We have
studied potential biomarkers in patients with various stages of TB infection and with border-
line QFT tests compared to those with higher values.
Methods
27 soluble biomarkers were analysed in QFT supernatants from patients with active TB
(n = 18), individuals with LTBI (n = 48) and from QFT negative controls (n = 16) by the Multi-
plex bead assay. The LTBI group was classified into two groups according to QFT IFN-
levels; QFT borderline (0.35–0.70 IU/mL, n = 11) or QFT high ( 0.70 IU/mL, n = 36).
Results
The levels of IL-1ra, IL-2, IL-13, IL-15, IFN- , IP-10 and MCP-1 in background corrected TB
antigen stimulated supernatants (TBAg-Nil) significantly distinguished both active TB and
LTBI QFT high groups from the QFT negative controls (p0.004). In addition, IL-1ra, IL-2
and IP-10 significantly differentiated the QFT borderline group from the controls (p0.001).
Still, in the QFT borderline group the IL-1ra and IP-10 levels were not significant different
from neither the QFT high nor the active TB group, whereas the IL-2 levels were lower
(p0.003). The level of IP-10 showed the best separation between the QFT borderline
group and the QFT negative controls (AUC 0.92) and offered 100% sensitivity for active
TB.
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Conclusion
IL-1ra, IL-2 and IP-10 differentiate QFT borderline samples from uninfected controls and
the majority of QFT borderline subjects were classified as LTBI by these markers. Still,
inconsistency was seen, and further studies are needed to examine the performance of
alternative markers before concluded if they could be used as diagnostics tools.
Introduction
Screening for latent tuberculosis infection (LTBI) has traditionally been performed by the
tuberculin skin test (TST), but during the last years interferon gamma (IFN- ) release assays
(IGRAs) have been increasingly used for this purpose. IGRAs offer better specificity than the
TST, but have suboptimal sensitivity in children and human immunodeficiencyvirus (HIV)
co-infected individuals, and the tests cannot distinguish between active tuberculosis (TB) and
LTBI [1]. This limits their use in high TB incidence areas where the burden of LTBI and HIV
co-infection is high. In addition, studies of IGRAs for serial TB screening of health care workers
(HCW) [2,3] and in HIV infection [4,5] have shown that the interpretation of IGRA results is
complicated by relative high rates of conversions and reversions and within subject variability.
Subjects with QuantiFERON-TB (QFT) baseline results around the diagnostic cut off are more
likely to have inconsistent results on serial testing, and a systematic review suggests introduc-
tion of a borderline zone for QFT when screeningHCW [2]. It has also been shown that there
is substantial variability in QFT response when the test is repeated in the same patient sample
[6]. As strategies for TB control and elimination include preventive therapy to individuals with
LTBI to reduce the risk for development of active disease, there is a need of more robust and
reliable diagnostic tools which can differentiate TB infected from non-infected individuals.
Several studies aiming to identify alternative biomarkers for use in TB diagnostics have been
conducted. IFN- inducible protein 10 (IP-10) is the most studied soluble biomarker, and a
review by Ruhwald et al concludes that whereas IP-10 based tests perform comparably to QFT
in most patient groups, it seems to be more robust in children and HIV-infected individuals
[7]. However, IP-10 has not been studied for use in serial testing. Further, although several
markers or combination of markers have been suggested that may differentiate between the
various stages of TB infection [8–12], no obvious candidate has been identified [13].
The aims of this study were to examine the potential of 27 different soluble markers detected
in QFT supernatants to differentiate between the various stages of TB infection and to compare
the pattern of markers in subjects with QFT test results in the borderline zone with those with
higher values as well as with QFT negative controls. We show that the background corrected
TB antigen stimulated levels (TBAg-Nil) of seven soluble markers (IL-1ra, IL-2, IL-13, IL-15,
IFN- , IP-10 and macrophage chemoattractant protein 1 (MCP-1)) distinguished both the
active TB and LTBI groups from the QFT negative controls. The level of IL-1ra, IL-2 and IP-10
also differentiated the QFT borderline group from the controls, supporting true TB infection in
the majority of these patients.
Material and Methods
Study participants
Persons referred to the TB clinic at Haukeland University Hospital, Bergen, Norway for QFT
testing and medical evaluation of LTBI based on known exposure of TB or origin from a high
Cytokine Patterns in Tuberculosis
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TB endemic country with a concomitant positive TST and patients diagnosedwith active TB
admitted to the inpatient ward, were included in a study of the performance of IGRA in clinical
practice [14].
The diagnosis of active TB was based on a positiveMycobacterium tuberculosis (Mtb) cul-
ture or on clinical and radiological findings. Subjects with no signs of active TB based on X-ray,
sputum or biopsy examination and clinical evaluation, and with a positive QFT test were
defined as LTBI and offered preventive anti-TB chemotherapy with isoniazid and rifampicin
for 3 months. A repetitive QFT test was performed during the first year after preventive ther-
apy was ended. None of the study participants were HIV infected. The LTBI group were further
classified according to QFT values 0.35–0.70 IU/mL (QFT borderline) or> 0.70 IU/mL (QFT
high).
Written informed consent was obtained from all participants. The study was approved by
the Regional Committee for Ethics in Medical Research (REK-Vest, 3.2005.823), Norway.
QuantiFERON-TB GOLD in-tube assay
The assay was performed according to the manufacturer’s instructions (Cellestis Ltd, Qiagen,
Chadstone, VIC, Australia). One ml of whole bloodwas added to each of the three QFT tubes
containing TB antigen (ESAT-6, CFP-10 and TB 7.7), mitogen-positive control (phytohemag-
glutinin (PHA)) and a negative control, respectively. The tubes were incubated at 37°C for 16–
24 h, centrifuged and the supernatant removed. The amount of IFN- in the supernatant was
quantified by enzyme-linked immunosorbent assay (ELISA). The level of IFN- in the TB anti-
gen (TBAg) tube was corrected for background by subtracting the IU⁄ml value obtained for the
respective negative control tube (Nil). The cut-off value for positive test (TBAg-Nil)
was 0.35 IU⁄ml. The excess of supernatants from the QFT tubes were frozen and stored at
-80°C until further analysis.
Multiplex cytokine analysis
Levels of biomarkers in QFT supernatants were measured using Bio-Plex Pro Human Cytokine
Group 27-Plex Panel (Bio-Rad Laboratories Inc., Hercules, CA) on a Luminex 100 platform
according to the manufacturer’s instructions. Levels of interleukin (IL)-1 , IL-1 receptor antag-
onist (IL-1ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17,
basic fibroblast growth factor (basic FGF), eotaxin, granulocyte colony stimulating factor
(G-CSF), granulocytemacrophage colony stimulating factor (GM-CSF), IFN- , IP-10, MCP-1,
macrophage inflammatory protein 1 alpha (MIP-1 ), MIP-1 , platelet-derived growth factor
-BB (PDGF-BB), regulated on activation, normal T cell expressed and secreted (RANTES),
tumor necrosis factor- (TNF- ) and vascular endothelial growth factor (VEGF) were ana-
lysed in supernatants both from the unstimulated (Nil) and the TB antigen stimulated QFT
tubes (TBAg). Supernatants from the mitogen stimulated QFT tubes were not analysed. The
supernatants were diluted 1:4 in Bio-Plex sample diluent, and levels obtained were therefore
multiplied by four to correct for the dilution. STarStation v.3 software was used for data
analysis.
For three of the 27 markers analysed (IL-8, MIP-1 and RANTES), a considerable propor-
tion of the study subjects in both the active TB and LTBI groups had both TBAg and Nil levels
that were above the upper detection limit (UDL) of the assay despite dilutions. Thus, these
TBAg-Nil results were excluded from all statistical analyses. This pattern was also found for
IP-10 and MCP-1, but only for the TBAg samples. Thus, the TBAg-Nil results of IP-10 and
MCP-1 were not used in statistical analyses when the active TB and LTBI groups were com-
pared, whereas when comparing the two TB infection groups with the controls the TBAg levels
Cytokine Patterns in Tuberculosis
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above the UDL were replaced by the highest value of the standard curve for the respective
marker to allow non-parametric statistical analysis. Thus, when comparing the level of some
markers both within the TB infection groups and with the controls, significant differencesmay
not be detected because the actual median levels in the active TB and LTBI group may be
higher than we were able to detect within the range of the assay. Also occasional values (<15%
of the total data set) above the UDL for some of the other markers (IL-1 , IL-6 and MIP-1 ),
were replaced by the highest value of the standard curve. The level of IL-5 was below the lower
detection level (LDL) of the assay in>75% of all samples, and were therefore excluded from all
statistical analysis. For the other markers, the occasional values (<10% of the total data set)
below the LDL were replaced by a defined common value below the LDL (0.001), which
allowed non-parametric statistical analysis.
Statistical analysis
All statistical analyses were performed using IBM SPSS statistics 21 and GraphPad Prism 6.
The unstimulated level (Nil) and the background corrected TB stimulated level (TBAg-Nil) of
each marker were included as separate variables in the statistical analyses.
Mann-Whitney U test was used to detect differences between the study groups. Wilcoxon
matched pairs signed rank test was used to detect differences in the level of markers before and
after prophylactic anti-TB chemotherapy. The general significance level was set to 0.05. In a
preliminary step, the Spearman correlations between all pairs of biomarkers were calculated,
showing a high proportion of correlated variables. Taking into account multiple testing effects
the Bonferroni adjustment would be too conservative due to the dependence between the
markers. Thus, we decided to use a marginal level of 0.005 (corresponding to Bonferroni
adjustment for 10 tests).
Receiver operator characteristic (ROC) curve analyses were performed for the markers
which, by the aforementioned tests, significantly differentiated between the LTBI borderline
group and the QFT negative group. The optimal cut-off levels were defined by the minimum
Euclidian distance to maximal specificity and sensitivity.
Results
Study participants
A total of 82 study participants had stored QFT supernatants available for Multiplex analysis,
and these were classified into three groups; 1) active TB (n = 18), 2) QFT positive LTBI
(n = 48), and 3) QFT negative controls (n = 16). Eleven of the QFT positive LTBI individuals
were further classified as QFT borderline, 36 as QFT high and in one IFN- level was not deter-
mined. Fifteen individuals with LTBI had available repetitive samples obtained during the first
year after preventive therapy. The clinical characteristics of the study participants are summa-
rized in Table 1.
The diagnosis of active TB was based on a positiveMtb culture in 16 of the patients, whereas
in two patients the diagnosis was based on clinical and radiological findings. Fourteen patients
had pulmonary TB and four extrapulmonary TB, and there were no multi- or extensively drug-
resistant TB cases.
Cytokine patterns in latent and active TB infection
Twenty-seven different cytokines, including chemokines and markers of inflammation, were
analysed in QFT supernatants and compared in patients with various stages of TB infection
and with QFT negative controls. We first examined if there were any differences between
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patients with active TB and LTBI. For the markers within the range of the assay, we found no
significant differences in TBAg-Nil levels between the active and the LTBI group. In contrast
the Nil levels of IL-1 , IL-1ra, IL-9 and IL-17a were significantly lower in the active TB group
compared with the LTBI group (p0.004, Fig 1).
Table 1. Clinical characteristics of the study participants.
Active TB, (n = 18) LTBI QFT high (n = 36) LTBI QFT borderline (n = 11) QFT negative (n = 16)
Age; median (range) 32 (18–62) 40 (13–67) 40 (25–53) 47 (16–68)
Sex; males/females 6/12 13/23 4/7 8/8
Origin; TB high/low endemic country 16/2 22/14 9/2 4/12
LTBI QFT borderline = 0.35–0.70 IU/ml. LTBI QFT high 0.70 IU/mL.
*In total, n = 48 QFT positive individuals with LTBI were included in the study, but for one them the exact value of the QFT-test was not known. This subject
was therefore excluded from the subgroup analyses.
doi:10.1371/journal.pone.0163848.t001
Fig 1. Markers differentiating between active and latent TB infection. Nil levels (pg/mL) of IL-1 , IL-1ra, IL-9 and IL-17a in patients with active TB
(ATB), latent TB infection (LTBI) and in QFT negative controls (QFT negative). The horizontal lines show the median values. Mann-Whitney U test was used
for comparison between groups. Brackets represents statistically significant differences (p0.004).
doi:10.1371/journal.pone.0163848.g001
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We then analysed if any marker could distinguish betweenTB infection and QFT negative
controls. We found that the TBAg-Nil levels of seven of the markers; IL-1ra, IL-2, IL-13, IL-15,
IFN- , IP-10 and MCP-1, were significantly higher in both the active TB and LTBI group than
in QFT negative controls (p0.004) (Fig 2).
In the unstimulated supernatants, the Nil level of IL-15, eotaxin and basic FGF were signifi-
cantly lower (p<0.0002) and the Nil level of RANTES significantly higher (p = 0.0003) both in
the active TB and LTBI groups compared with the QFT negative controls. The median Nil lev-
els of several other markers (IL-2, IL-4, IL-13, IL-17a and IFN- ) were also lower in the active
TB (p0.003) group than in controls (data not shown).
Fifteen of the study participants in the LTBI group (13/15 QFT high) had available superna-
tants fromQFT tests performed during the first year after prophylactic anti-TB chemotherapy.
There were no significant changes in the Nil or TBAg-Nil levels for any of the markers in
response to treatment, except from a decline in the Nil level of PDGF-BB (p = 0.002). Also the
TBAg-Nil level of IL-2, IFN- and IP-10 remained significantly higher than that seen in the
QFT negative controls indicating a maintained response to TB antigens (data not shown).
Cytokine patterns in subjects with borderline zone QFT responses. Finally, we investi-
gated if LTBI patients with borderline zone QFT IFN- values in the range 0.35–0.70 IU/ml,
close to cut-off for the QFT test, demonstrated a different cytokine pattern than LTBI patients
with higher QFT IFN- values> 0.70 IU/ml. The TBAg-Nil levels of IL-1ra, IL-2, IL-13, IL-15,
IFN- , IP-10, MCP-1 and IL-17a were all significantly higher in the QFT high group than in
the QFT negative controls (p0.004, Fig 2).
However, only the levels of IL-1ra, IL-2 and IP-10 significantly differentiated the QFT bor-
derline group from the QFT negative controls (p0.001) (Fig 2). Whereas the IL-1ra and IP-10
levels in the QFT borderline group were not significant different from neither the QFT high
nor the active TB group, the IL-2 level was significantly lower in the QFT borderline group
(p0.003). In the Nil supernatants, only IL-15 and basic FGF significantly differentiated the
QFT borderline group (lower levels) from the QFT negative controls (p0.0008), whereas for
the QFT high LTBI group a similar pattern as seen for the overall LTBI group was found (data
not shown).
The diagnostic accuracy of the TBAg-Nil levels of IL-1ra, IL-2 and IP-10 in differentiating
between the QFT borderline group and the QFT negative group were investigated by ROC
curve analyses. The AUC, p-value, optimal cut-off levels, sensitivity and specificity for the
respectivemarkers are given in Table 2. The TBAg-Nil level of IP-10 had the highest AUC
(0.92).
Based on the cut-off levels found by the ROC curve analyses, four subjects classified as LTBI
by the QFT test, two in the QFT borderline group and two in the QFT high group, were classi-
fied as not TB infected by IP-10, and two subjects classified as negative by the QFT test were
classified as LTBI (Table 3). IP-10 had a 100% sensitivity for active TB. IL-1ra and IL-2 classi-
fied four of the subjects in the QFT high group as not TB infected, and IL-2 also classified two
subjects in the QFT borderline group as not infected. In the QFT negative control group, four
and one subjects, respectively, were classified as LTBI by IL-1ra and IL-2. In total, 18/81 of the
study subjects were classified in discordance with the QFT test by one or several of the three
alternative markers. For eleven subjects only one of the markers showed a discordant result,
whereas for seven subjects two or all three of the alternative markers were discordant with the
QFT classification. In the QFT high group, four of the seven subjects that were classified in dis-
cordance with the QFT test by one or several of the three alternative markers, had low QFT test
values between 0.70–1.0 IU⁄mL.
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Discussion
We have examined the potential of several soluble chemokines and cytokinesmeasured in
QFT supernatants to diagnose and differentiate between the various stages of TB infection and
uninfected controls as well as the pattern of markers in subjects with QFT test result in the bor-
derline zone of 0.35–0.70 IU/mL.We found that the background corrected TB antigen stimu-
lated levels of sevenmarkers (IL-1ra, IL-2, IL-13, IL-15, IFN- , IP-10 and MCP-1)
distinguished both the active TB and LTBI group from the QFT negative controls. IL-1ra, IL-2
and IP-10 also differentiated the QFT borderline group from the controls, and these three
markers classified the majority of the study participants in the QFT borderline group in accor-
dance with the QFT test.
Previous studies of alternative biomarkers from analyses of QFT supernatants [8–11] have
found that unstimulated or TB antigen stimulated levels of various markers (EGF, MIP-1 ,
TGF- , IL-1 , sCD40L, VEGF, IFN- 2, IL-1ra, IP-10, IL-2, IL-15 and MCP-1) may have
potential for differentiating between active TB and LTBI. However, a review by Chegou et al
concludes that there is no clear pattern of markers that are able to differentiate between the var-
ious stages of TB infection [13]. In support of this we also did not find any marker that was
able to differentiate between active TB and LTBI when the background corrected TB antigen
stimulated levels were analysed. However, in the unstimulated Nil supernatants, the levels of
IL-1b, IL-1ra, IL-9 and IL17a were significantly lower in the active TB group compared with
the LTBI group. This confirms studies that report that unstimulated levels of IL-1ra differenti-
ate between active and latent TB in both children and adults [10,12].
In serial TB screening, relative high rates of conversions and reversions of QFT tests, espe-
cially around the diagnostic cut off, complicate the interpretation of IGRA results [2,3, 14]. A
large variation in both these rates has been reported from different studies of HCW in TB low
endemic countries (reversion rates 22–71% and conversion rates 1–14%) [2]. This was also
seen in a cohort of health care students from a high TB incidence setting in which the variation
could not be explained by occupational exposure [15]. Likewise, discordant IGRA results have
been found in repeated testing of HIV-infected individuals living in TB low-endemic countries
[4,5]. Pullar et al reportedQFT reversions rates in HIV patients with untreated LTBI and in
those receiving preventive TB therapy of 44% and 23%, respectively, during two years of fol-
low-up as well as a conversion rate of 7% in the TB negative control group despite no known
new TB exposure [4]. Finally, Metacalfe et al show that there is substantial variability in QFT
responses when the test is repeated in the same patient sample [6]. In studies performed in TB
Fig 2. Markers differentiating TB infection fromQFT negative controls. TB antigen stimulated
background corrected (TBAg-Nil) levels of IL-1ra, IL-2, IP-10, IFN- , IL-13, IL-15, IL-17a and MCP-1 in
patients with active TB (ATB), latent TB infected subjects with QFT result 0.70 IU/mL (LTBI QFT 0.7),
subjects with QFT result in the borderline zone 0.35–0.70 IU/mL (LTBI QFT 0.7) and in QFT negative
controls (QFT negative). The horizontal lines show the median values. Mann-Whitney U test was used for
comparison between groups. The TBAg-Nil level of IP-10 and MCP-1 were excluded from statistical analyses
when the LTBI and ATB groups were compared because high proportions of study subjects in both groups
had levels above the UDL of the assay. Brackets represents statistically significant differences (p 0.005).
doi:10.1371/journal.pone.0163848.g002
Table 2. ROC curve analyses for differentiation between the QFT borderline group and QFT negative controls.
Marker Cut-off (pg/mL) Sensitivity, % (95% CI) Specificity, % (95% CI) AUC (95% CI) p-value
IL-1ra (TBAg-Nil) 409 100 (72–100) 75(48–93) 0.852 (0.701–1.000) 0.002
IL-2 (TBAg-Nil) 37 82 (48–98) 94 (50–100) 0.875 (0.720–1.000) 0.001
IP-10 (TBAg-Nil) 4235 82 (48–98) 88 (62–98) 0.920 (0.821–1.000) 0.001
doi:10.1371/journal.pone.0163848.t002
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low-endemic countries, the relative high conversion rates have been considered a result of false
positive conversions. Thus, a borderline zone for QFT from 0.20–0.70 IU/mL has been sug-
gested in the screening of HCW [2]. Altogether, these data highlights the need for additional
markers to better discriminate between truly TB infected and uninfected individuals in order
to identify those that should be offered preventive TB therapy.
In this study, the background corrected TB antigen stimulated levels of three markers, IP-
10, IL-1ra and IL-2, differentiated the QFT borderline group from the QFT negative controls.
ROC curve analyses for differentiation between these two groups showed that IP-10 had the
highest AUC (0.92) and a sensitivity and specificity of 82 and 88% respectively, whereas IL-1ra
had better sensitivity (100%) and IL-2 better specificity (94%). Based on the cut off levels found
by the ROC curve analyses, IP-10, IL-1ra and IL-2 classifiedmost of the study subjects as TB
infected or not-TB infected in accordance with the QFT test. However, a few subjects in the
active TB group were wrongly classified as not-TB infected by IL-2 and IL-1ra whereas some of
the QFT negative subjects were classified as TB infected by the study markers. IP-10 had 100%
sensitivity for active TB and classified two subjects in the QFT borderline zone as not TB. It is
of interest that four of seven subjects in the QFT high group classified as not-TB by one or sev-
eral of the three aforementioned markers had rather low QFT test results in the range of 0.70–
1.0 IU/mL. Altogether this may indicate that a broader QFT borderline zone is more appropri-
ate or at least that a positive QFT test in the lower range of the assay must be interpreted with
caution. Still, the cut-offs from these limited ROC analyses can not at this stage be used as diag-
nostic tools in clinical practice as the data need to be validated in larger prospective studies.
IL-1ra, IL-2 and IP-10 have previously been suggested as diagnostic biomarkers for TB
infection and IP-10 is the most extensively studied [7,13]. Although IP-10 is mainly secreted by
antigen presenting cells (APCs), secretion is initiated by T cell recognition of specific peptides
presented by APCs, and mainly driven by T cell derived IFN- . In accordance with our results,
Ruhwald et al found that TB stimulated levels of IL-1-ra were significantly higher in patients
with active TB compared with unexposed controls [16]. Frahm et al found the same pattern
when comparing TB infected (active and LTBI combined) with uninfected subjects, and also a
tendency of lower levels in LTBI versus active TB infection [11]. IP-10 and IL-2 offered compa-
rable or even better sensitivity than IFN- for detection of patients with active TB [17–19] on
support of our data. It has also been reported that the performance of IL-2 is similar to QFT in
TB exposed individuals [19,20]. Whereas IP-10 has been equal to QFT in some studies [21,22]
others have identified a higher number of infected contacts defined by IP-10 [19,20]. In our
study, IL-1ra, IL-2 and IP-10 classified four, one and two, respectively, of the 16 QFT negative
subjects as LTBI. To our knowledge, no studies of the variability of the alternative biomarkers
in serial testing have been performed.
Previous studies show that unstimulated plasma levels of IP-10 distinguish between active
and latent TB cases/household contacts [23,24]. We have also recently demonstrated that
plasma IP-10 distinguished active TB from LTBI irrespective of HIV-infection and declined
Table 3. Number of subjects classified as active TB and LTBI by IL-1ra, IL-2 and IP-10.
Marker Active TB (n = 18) LTBI QFT high (n = 36) LTBI QFT borderline (n = 11) QFT negative (n = 16)
IL-1ra 14 32 11 4
Il-2 17 32 9 1
IP-10 18 32* 9 2
*Two subjects in the LTBI QFT high group had an inconclusive IP-10 TBAg-Nil value because both the TBAg and the Nil value were out of range of the
assay.
doi:10.1371/journal.pone.0163848.t003
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during anti-TB chemotherapy [25]. In support of our data, Chegou et al also found that the IP-
10 Nil, but not TBAg-Nil level, in QFT supernatants distinguished between active TB and
LTBI in children [10]. However, in the present study and a previous study in adults [9], neither
the Nil nor the TBAg-Nil level of IP-10 in QFT supernatants were able to differentiate between
these stages of infection. This discrepancy could be due to differences in the handling of the
samples, the method of analysis and in the studied population.
There are some limitations to our study. Firstly, as there is no gold standard for diagnosing
LTBI, the diagnostic accuracy of alternative markers is difficult to assess. In this study the diag-
nosis of LTBI was based on information of TB exposure, clinical examination excluding active
TB and the QFT test result. Secondly, repeated testing of subjects with QFT test result in the
borderline zone was not performed and we were therefore not able to examine the variability of
IL-1ra, IL-2 and IP-10 in longitudinal samples. Thirdly, for some of the markers analysed, a
considerable proportion of the study subjects in both the active TB and LTBI had TB stimu-
lated and Nil levels that were above the upper detection level of the assay despite dilutions of
the samples. Differences in these markers between the TB infection groups could therefore not
be evaluated.When comparing the levels of these markers in TB groups with the controls, sig-
nificant differencesmay not be detected because levels that were above the upper detection
level were replaced by the highest value of the standard curve. The actual median levels in the
active and LTBI group therefore may be higher than we were able to detect. Still, significant
data presented in this study were all based on valid parameters. Finally, due to a small sample
size increasing the risk of type 2 errors the data needs to be confirmed in larger prospective
studies to determine whether the markers have reliable predictive capacity.
Conclusions
Analysis of unstimulated levels of IL-1b, IL-1ra, IL-9 and IL-17a in QFT supernatants may
help to discriminate active TB from LTBI whereas the respective TB antigen stimulated levels
do no separate between the groups. Still, TB antigen stimulated IL-1ra, IL-2 and IP-10 levels
differentiate the QFT borderline group from controls, supporting true TB infection in the
majority of these patients. However, inconsistency was seen and further studies are needed to
examine proper cut-offs and the variability of these markers in serial testing.
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Th1 effector and T regulatory cells in vitro
in Mycobacterium tuberculosis infection
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Abstract
Background: Tuberculosis (TB) causes a major burden on global health with long and cumbersome TB treatment
regimens. Host-directed immune modulating therapies have been suggested as adjunctive treatment to TB
antibiotics. Upregulated cyclooxygenase-2 (COX-2)-prostaglandin E2 (PGE2) signaling pathway may cause a
dysfunctional immune response that favors survival and replication of Mycobacterium tuberculosis (Mtb).
Methods: Blood samples were obtained from patients with latent TB (n = 9) and active TB (n = 33) before initiation of
anti-TB chemotherapy. COX-2 expression in monocytes and ESAT-6 and Ag85 specific T cell cytokine responses (TNF-α,
IFN-γ, IL-2), proliferation (carboxyfluorescein succinimidyl ester staining) and regulation (FOXP3+ T regulatory cells) were
analysed by flow cytometry and the in vitro effects of the COX-1/2 inhibitor indomethacin were measured.
Results: We demonstrate that indomethacin significantly down-regulates the fraction of Mtb specific FOXP3+ T
regulatory cells (ESAT-6; p = 0.004 and Ag85; p < 0.001) with a concomitant reduction of Mtb specific cytokine
responses and T cell proliferation in active TB. Although active TB tend to have higher levels, there are no significant
differences in COX-2 expression between unstimulated monocytes from patients with active TB compared to latent
infection. Monocytes in both TB groups respond with a significant upregulation of COX-2 after in vitro stimulation.
Conclusions: Taken together, our in vitro data indicate a modulation of the Th1 effector and T regulatory cells in Mtb
infection in response to the COX-1/2 inhibitor indomethacin. The potential role as adjunctive host-directed therapy in
TB disease should be further evaluated in both animal studies and in human clinical trials.
Keywords: Tuberculosis, COX-inhibitors, Tregs, Regulatory T cells, Host-directed therapy, Monocytes, Cytokines
Background
Infection with Mycobacterium tuberculosis (Mtb) causes a
major burden on global health with 9 million people suffer-
ing from tuberculosis (TB) disease and with 1.5 million
deaths every year [1]. The current TB treatment strategies
consist of long lasting multiple drug regimens with risk of
serious side-effects and development of multi-drug resistant
TB (MDR-TB). Host-directed therapies (HDTs) in conjunc-
tion with standard anti-TB drug regimens may reduce the
duration of therapy, achieve better treatment outcomes,
lower the risk of developing further drug resistance and
decrease the chances of relapse or reinfection [2, 3].
In chronic infections such as TB, immune-mediated tissue
injury may become more detrimental than the pathogen
itself and the immune system have evolved mechanisms to
balance pro and anti-inflammatory signals [4]. FOXP3+ T
regulatory cells (Tregs) are involved in the regulation of in-
flammatory processes and exert immunosuppressive func-
tions by cell contact-dependent suppression of CD4+ T cells
and by secretion of inhibitory cytokines and soluble factors
[5, 6]. Tregs may dampen protective immunity facilitating
pathogen multiplication and dissemination [7] and may also
limit vaccine immunogenicity [8]. Thus, targeting of Tregs
may have potential as host directed adjunctive therapies [9].
Prostaglandin E2 (PGE2) is generated by the constitutive
cyclooxygenase 1 (COX-1) and the inducible cyclooxygenase
2 (COX-2) enzymes and is regarded as a key mediator of im-
munopathology with immune regulatory effects in chronic
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infections [10, 11]. Macrophages and monocytes up-regulate
COX-2 enzymes in response to inflammatory signals and
are thereby major producers of PGE2 and other eicosanoids
[12]. Monocytes as well as adaptive Tregs seem to inhibit
effector T cell functions and suppress T cell immune re-
sponses by a COX-2-PGE2-dependent mechanism [13–15].
It has been shown that highly expressed COX-2 in malig-
nant tissue is associated with poor prognosis and outcome
in cancer disease [16, 17]. However, no data exists on COX-
2 expression of immune cells in human TB disease.
Standard TB antibiotics are directed against the pathogen,
but various host directed immune therapies, including
reduction of PGE2 production by COX- inhibitors (COX-i)
has potential to become part of a treatment strategy for
resistant or clinically complicated TB cases or as part of a
TB vaccination scheme [18–20]. Accordingly, studies of TB
animal models have shown that targeting PGE2 with COX-i
have significant impact on the immune responses and
outcome of disease [21–25]. Based on these data, it is
suggested that a human intervention study with anti-
inflammatory drugs given in combination with anti-TB
chemotherapy should be performed [24]. Clinical trials in
HIV infected patients have also shown that COX-i improve
Tcell mediated immune responses [26–28].
Indomethacin is a widely used non-steroidal anti-
inflammatory drug (NSAID) of the methylated indole class
with analgesic and antipyretic properties exerting its
pharmacological effects by inhibiting the synthesis of prosta-
glandins via the arachidonic acid pathway [29]. Indometh-
acin inhibits both COX-1 and COX-2 with greater
selectivity for COX-1 [30] and due to water soluble charac-
teristics the compound is practical to use in in vitro studies.
Indomethacin has previously been shown to increase the
bactericidal activity of Mtb infected macrophages [31] and
to improve T cell proliferative responses in HIV-infected pa-
tients [28], but to our knowledge the effect of indomethacin
on Tcell responses has not been studied in TB infection.
The objective of this study was to analyze COX-2
expression in monocytes from patients with latent and
active TB and to explore the in vitro effects of the COX-i
indomethacin on Mtb-specific T cell responses and regula-
tion. We show that indomethacin down-regulates Mtb anti-
gen stimulated Tregs, antigen induced cytokine responses,
in particular TNF-α+ cells, and Tcell proliferation. Our data
suggest a potential role for COX-i in modulation of immune
responses in TB infection. However, the functional conse-
quences of our data need to be further evaluated and the
potential for COX-i as HDT in TB infection should be ex-
plored in both animal studies and in human clinical trials.
Methods
Study participants
Ten patients with active TB disease (ATB) and nine pa-
tients with latent TB (LTB) were recruited from Haukeland
University hospital, Bergen, Norway (cohort A). Additional,
23 patients with active TB disease were recruited from
Oslo University hospital, Oslo, Norway (cohort B). Table 1
summarizes demographic and clinical patient characteris-
tics. All patients were HIV uninfected. The diagnosis of
active TB was based on a positive Mtb culture or on
clinical and radiological findings. Subjects with a positive
QuantiFERON®-TB test and with no signs of active TB
based on X-ray, sputum or biopsy examination and clinical
evaluation were defined as LTB.
Sample processing
Blood samples were obtained before initiation of anti-TB
chemotherapy. Peripheral blood mononuclear cells (PB
MCs) from participants recruited in cohort A were iso-
lated using density gradient centrifugation (Lymphoprep™,
Fresenius Kabi Norge AS, Halden, Norway), cryopreserved
in 10 % DMSO/90 % fetal bovine serum (FBS, GIBCO,
Life technologies) and stored in liquid nitrogen until
analysis. PBMCs from participants recruited in cohort B
were isolated in cell preparation tubes (CPT) (Becton
Dickinson, BD, New Jersey, USA) with sodium heparin
and cryopreserved in 90 % fetal calf serum (FCS, Sigma,
Missouri, USA)/10 % DMSO and stored at −145 °C until
analysis. Participants recruited in cohort A were only
included in the monocyte assay and participants recruited
in cohort B were only included in the Treg, proliferation
and intracellular cytokine assays. Therefore, all assays only
included PBMCs isolated by either of the methods.
Figure 1 gives an overview of the number of samples used
in the different assays in the study.
Table 1 Patient characteristics
Cohort A Cohort B
ATB (n = 10) LTB (n = 9) ATB (n = 23)
Age (median years, range) 28 (16–72) 43 (26–67) 29 (20–60)
Female (%) 3 (30) 4 (44) 9 (39)
Origin (%)
Africa 4 (40) 4 (44) 10 (43)
Asia 2 (20) 2 (22) 10 (43)
Europe 4 (40) 3 (33) 3 (14)
Localisation (%)
Pulmonary 10 (100) - 17 (74)
Extrapulmonarya - - 6 (26)
ESRb (median mm/
hour, range)
42 (21–77) 16 (7–23) 21 (1–103)
Characteristics of patients included at Haukeland University hospital, Bergen,
Norway (cohort A) and Oslo University hospital, Oslo, Norway (cohort B)
ATB active TB, LTB latent TB
aglandular, pericardial, pleural
bErythrocyte Sedimentation Rate
Tonby et al. BMC Infectious Diseases  (2016) 16:599 Page 2 of 12
Detection of COX-2 in monocytes
Cryovials from active and latent TB patients were thawed,
washed and resuspended in RPMI-1640 media (Sigma-Al-
drich) with 10 % FBS. PBMCs with viability <70 % were ex-
cluded from further analyses. After resting 6 h, PBMCs
were allocated to a monocyte assay for 12 h stimulation
with Lipopolysaccharide (LPS) (10 ng/mL, Sigma-Aldrich)
or unstimulated RPMI media. The cells were stained with
Live/Dead discriminator, followed by cell surface staining
of CD3, CD4, CD14, CD16 and HLA-DR and intracellular
staining of COX-2. The following live/dead discriminator
stain and directly conjugated monoclonal antibodies were
used in the monocyte assay: Live/Dead Fixable Near-IR
Dead Cell Stain kit (Life technologies), anti-CD3-PE-Cy7,
anti-CD4-Horizon V500, anti-CD14-APC, anti-CD16-PE,
anti-HLA-DR-BV421 (all from BD Bioscience) and anti-
COX-2 (Cayman Chemicals, Ann Arbor, MI, USA).
Human FOXP3 buffer set (BD bioscience) was used for
fixation and permeabilisation.
T regulatory cells and intracellular cytokine assays
PBMC’s (0.75 -1 × 106 cells/well) from patients with un-
treated active TB were rested 6 h before stimulation with
Mtb derived 6 kDa early secretory antigenic target (ESAT-
6, 2 ug/ml) and Antigen 85 (Ag85, 2 ug/ml) complex (both
15mer overlapping peptide, Genscript, HK limited; >85 %
purity). The samples were stimulated with or without the
COX-i indomethacin (25 μM, Sigma Aldrich). Staphylo-
coccal enterotoxin B (SEB) (1 ug/ml, Sigma-Aldrich) was
used as positive control and serum-free medium (AIM V;
Gibco Invitrogen, Carlsbad, CA, USA) with 0.1 % highly
purified human albumin as negative control. Due to
limited number of cells indomethacin was not added to the
SEB stimulated samples. Only PBMCs with viability >80 %
were included. Samples with COX-i were pre-treated with
indomethacin 2 h before stimulation and then incubated
for 12 and 36 h. In the 12 h assay, Brefeldin A (BFA), final
concentration 10 ug/ml (BD Bioscience) was added at time
of stimulation, whilst in the 36 h assay BFA was added for
the last 10 h to avoid prolonged incubation with potential
toxic effects of BFA [32]. In both the 12 and 36 h assay, the
cells were washed and stained with live/dead discriminator
in azide-free and serum/protein-free PBS followed by CD4,
CD3 and CD25 surface staining. The samples were washed
and fixed/permeabilized with the FOXP3 staining kit (BD
Biosciences) according to the manufacturer’s instructions.
Subsequently, cells were stained for intracellular TNF-α,
IFN-γ, IL-2 and FOXP3. The following reagents were used
in the 12 and 36 h stimulation assays for detection of
intracellular cytokines and Tregs: anti-CD4- APC- H7,
anti-CD3-PerCP-Cy5.5, anti-CD25-BV605, anti-IL-2-PE,
anti-IFN-γ- PE-Cy7, anti-TNF-α- APC, anti-FOXP3- AF
488 (all from BD Bioscience) and Fixable Viability Dye
eFluor® 450 (eBioscience, San Diego, USA).
CFSE proliferation assay
PBMCs (5 × 105cells/well) from active TB patients were
thawed and rested 6 h before labeling with Carboxyfluores-
cein succinimidyl ester (CFSE) according to manufacturer’s
procedure. In the COX-i treated samples, indomethacin
was added 2 h prior to stimulation with ESAT-6 and Ag85.
The samples were incubated for 6 days and then washed
Fig. 1 Flowchart of patient samples. Patients were included at two study locations. Cohort A (latent TB and active TB) denotes patients included
at Haukeland University Hospital, whilst cohort B denotes patients included at Oslo University Hospital. The figure also shows the distribution of
patient samples in the different assays performed in the study
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and stained for surface markers and viability staining.
Fluorochromes used in the 6 days proliferation assay; anti-
CD3-V450, anti-CD4- APC H7, anti-CD45RA -BV 605,
anti-HLA DR- APC, anti-CD25-PE, anti-CD127- PeCy7
and 7AAD- PerCP (all from BD Bioscience) and Cell-
Trace™ CFSE Cell Proliferation (Life technologies).
Flow cytometry analyses
Flow cytometric acquisition was performed on a BD FACS
Canto II and a BD LSR Fortessa flow cytometer. At least
10.000 CD4+ and CD8+ T cells were analyzed for the
intracellular analyses of cytokines and FOXP3 expression
in T cells and minimum 1.000 monocytes were required
for the analyses of COX-2 expression in monocytes. FlowJo
version 10 (TreeStar Inc, Ashland, OR, USA) was used for
data analyses. Dead cells were excluded from the lympho-
cyte and monocyte populations before applying the differ-
ent gating strategies. In the cytokine analyses, frequencies
(percentage of parent population) of Mtb antigen stimu-
lated cytokine producing T cells were calculated. Total
IFN-у+, IL-2+ or TNF-α+ describe all CD4+ or CD8+ cells
positive for the cytokine measured, while Boolean gating
strategy was used to create cytokine combinations defined
as: polyfunctional (IFN-у+IL-2+TNF-α+), double positive
(IFN-у+IL-2+ or IL-2+TNF-α+or IFN-у+TNF-α+) and sin-
gle positive (IFN-у+ or IL-2+ or TNF-α+) producing CD4+
and CD8+ T cells. Tregs were defined as FOXP3+CD25+
+CD4+ or as FOXP3+ CD45RA-CD4+ T cells [33]. In the
T cell proliferation assay, cut-off for proliferating cells was
set to the peak of the 2nd generation of CFSEdim CD4+ or
CD8+ T cells. Frequencies (percentage of parent popula-
tion) of Mtb antigen-stimulated cytokine-producing T cells,
Tregs and proliferation T cells are all shown without
subtracting background values (unstimulated controls) to
better delineate the effect of indomethacin on stimulated
versus unstimulated samples. Monocytes were defined as
“true monocytes” after exclusion of CD3+ and CD16
+HLA-DR- cells [34] and COX-2 expression (percentage
of parent population) by true monocytes was analysed. The
statistical region in the monocyte population was set by
use of COX-2 human blocking peptide (Cayman chemi-
cals) according to the manufacturer’s instructions.
Statistical analyses
Statistical analyses were performed by SPSS statistics 22
(IBM) and Statistica v 7.0 (Statsoft, Tulsa, OK, USA).
Non-parametrical statistical methods were applied. For
group-wise comparison Mann-Whitney U test was
applied and for dependent variables the two-tailed
Wilcoxon matched pair test. A significance level of 0.05
was used. All values are presented as median and inter-
quartile range [IQR]. Graphical presentations were made
using Prism V5.04 and V6 software (GraphPad, San
Diego, USA).
Results
COX 2 expression in monocytes in active and latent
tuberculosis
We first analyzed COX-2 levels in monocytes from
patients with latent or active TB (gating strategy, Fig. 2a).
Although not significant, unstimulated monocytes from
patients with active TB tended to express higher levels
of COX-2 compared to patients with latent TB (Fig. 2b).
Still, monocytes from both TB groups were able to
significantly up-regulate COX-2 expression after 12 h in
vitro LPS stimulation (Fig. 2b).
Indomethacin reduces up-regulation of Mtb antigen
induced FOXP3+CD25++ Tregs
We then assessed the in vitro effects of the COX-i indo-
methacin on Tregs from patients with active TB disease
prior to initiation of anti-TB chemotherapy (Fig. 3). FOXP3
+CD25++ Tregs were analyzed after 36-h TB antigen
stimulation, shown to be the optimal time for analyzing
FOXP3 changes in Tregs [35]. We observed a significant
up-regulation both in the fraction and the median
fluorescence intensity (MFI) of FOXP3+CD25++ Tregs in
the ESAT-6 and Ag85 stimulated CD4+ T cells with a
significant reduction in the samples treated with indometh-
acin both for the fraction of FOXP3+CD25++ Tregs (ESAT-
6; p= 0.004 and Ag85; p < 0.001) (Fig. 3a) and FOXP3 MFI
(unstim; p= 0.024 and Ag85; p= 0.023) (Fig. 3b).
Indomethacin reduces Mtb antigen induced T cell
cytokine production
To assess the effect of indomethacin on Mtb specific CD4
+ T cells, we stimulated cells with Mtb peptides with or
without addition of indomethacin and measured intracellu-
lar cytokine production after 12 and 36 h. There were
significant up-regulation of CD4+ T cell subsets producing
both IL-2, TNF-α and IFN-γ, in ESAT-6 stimulated cells
already after 12 h and in Ag85 stimulated samples also
after 36 h (Fig. 4). Indomethacin reduced the fraction of
total IL-2 producing cells after 12 h (ESAT-6; p = 0.032)
(Fig. 4a) and the fraction of total TNF-α producing cells
after 36 h stimulation (ESAT-6; p = 0.002 and Ag85; p =
0.026) (Fig. 4b), whereas no significant changes were seen
for the IFN-γ producing cells.
Single, double and polyfunctional CD4+ T cells were
also determined. After 12 h of stimulation there was no
clear pattern in response to indomethacin (Fig. 5a). The
TNF-α+IFN-γ+CD4+ cells demonstrated a slight
increase (ESAT-6; p = 0.023), whilst single TNF-α+ cells
decreased (Ag85; p = 0.043). However, after 36 h stimula-
tion, we observed a more distinct pattern in cells treated
with indomethacin with down-regulation of the follow-
ing cytokine producing CD4+ T cell subsets; IFN-γ+IL-2
+TNF-α+T cells (Ag85; p = 0.030), IL-2+TNF-α+(ESAT-
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6; p = 0.046 and Ag85; p = 0.007) and single-TNF-α+
cells (ESAT-6; p = 0.011 and Ag85; p = 0.031) (Fig. 5b).
CD8+ T cells also significantly up-regulated their
cytokine production upon Mtb antigen stimulation, but
the effect of indomethacin was less pronounced.
Overall there was a decrease in cytokine production,
but only significant for total IFN-γ+ and polyfunctional
IFN-γ-+IL-2+TNF-α+CD8+ T cells after 36 h stimula-
tion (ESAT-6; p = 0.039 and p = 0.017, respectively)
(data not shown).
Indomethacin modulates Mtb antigen induced T cell
proliferation
The proliferative capacity of Mtb peptide stimulated
CD4+ and CD8+ T cells was assessed by CFSE staining
in a 6 days stimulation assay. There was a significant in-
crease in both proliferating CD4+ (ESAT-6 and Ag85; p
< 0.001) and CD8+ T cells (ESAT-6 and Ag85 p < 0.001)
in stimulated compared to unstimulated cells (Fig. 6). A
significant, but modest, decrease of proliferating CD4+
T cells was observed in the indomethacin treated ESAT-
A
B
Fig. 2 COX-2 expression in monocytes. a Gating strategy for identification of true monocytes [34]. b Comparison of COX-2 expression in unstimulated
true monocytes in PMBCs from patients with latent TB (LTB, circles) and active TB (ATB, squares). PBMCs from patients with LTB and ATB were left
unstimulated (Unstim) or stimulated for 12 h with LPS. P- values were calculated by Wilcoxon matched pairs test for paired samples and Mann-
Whitney U test for group wise comparison (n.s = non-significant). Horizontal lines in b represent median values
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6 stimulated samples (p = 0.008) (Fig. 6a), whilst no sig-
nificant changes were seen in the Ag85 stimulated sam-
ples. For the CD8+ subsets, indomethacin likewise
reduced proliferation of Ag85 stimulated cells (p = 0.002)
(Fig. 6b). Cell surface activation markers were also
analyzed after 6 days stimulation and showed a decrease
in the fraction of activated CD25+HLA-DR+ (ESAT-6;
p = 0.011 and Ag85; p = 0.044) CD4+T cell subsets in
response to indomethacin treatment (data not shown).
Discussion
Host-directed immune modulating therapies have been
suggested as adjunct treatment in combination with
standard anti-TB antibiotics. Anti- inflammatory drugs
such as corticosteroids are already in use as adjunctive
therapy in TB meningitis with reduction of both
morbidity and mortality [36]. Non-steroid Anti- inflam-
matory drugs (NSAIDS) are already in use to relieve
symptoms in non-severe cases of paradoxical TB-IRIS
[37] and there are anecdotal reports of use of NSAIDS
in complicated cases of TB disease, however such prac-
tice is poorly documented in literature. In this study we
explored the in vitro effects of the COX-i indomethacin
on immune cells obtained from patients with active TB
disease prior to initiation of anti-TB chemotherapy. We
demonstrate for the first time that indomethacin signifi-
cantly down-regulates the fraction of Mtb antigen in-
duced Tregs as well as T cell proliferation and TNF-α
cytokine production.
First, we explored COX-2 expression in monocytes,
the major source for PGE2 production in a small cohort
of active and latent TB infection. Monocytes from pa-
tients with active TB exhibit functional and phenotypical
alterations compared with healthy controls [38, 39] that
could be restored by TB treatment [40]. Different species
of mycobacteria have been suggested to induce expres-
sion of COX-2 through different signaling pathways
[41]. To our knowledge, there are no previous studies
comparing COX-2 expression in latent versus active TB
in humans. Interestingly, we found a tendency of higher
spontaneous expression of COX-2 in the unstimulated
A
B
Fig. 3 Effect of indomethacin on TB antigen induced FOXP3+CD25++
CD4+ Tregs. PBMCs were obtained from patients with active TB (n= 17)
prior to treatment and left unstimulated (unstim) or stimulated for 36 h
with ESAT-6 or Ag85 without (open boxes) or with (hatched boxes)
addition of indomethacin. The figures show percentages of FOXP3
+CD25++ (a) and FOXP3 median fluorescence intensity (MFI) (b) in the
CD4+ cells. P- values were calculated by Wilcoxon matched pairs test.
Plots are shown as box plots together with individual data points with
median, IQR and minimum/maximum values. Significant changes
between stimulated samples with and without indomethacin are
denoted with p-values in figure. Levels of FOXP3+CD25++ CD4+ T cells
and FOXP3 MFI were significantly upregulated upon stimulation with
both E6 and Ag85 (p< 0.01, values not shown in figure)
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active TB compared to the latent TB samples, possibly
indicating an ongoing activation of the COX-2-PGE2
pathway in patients with active disease. However, as
shown by our data, also in otherwise healthy patients
with latent TB high levels of COX-2 could be expressed.
Thus, COX-2 levels in monocytes at different stages of
TB infection and any implication for disease progression
needs to be further studied in larger cohorts.
The main finding in our study was the reduction of anti-
gen induced Tregs in the indomethacin treated samples.
Of note, indomethacin also reduced the levels of FOXP3
MFI in the unstimulated samples, although to a lesser
extent than seen in the stimulated samples. This possibly
reflects an up-regulated COX expression and increased
PGE2 production in vivo in patients with active TB. There
are several reports of increased levels of Tregs in TB
disease [42–44], but the role of these immune regulatory
cells during chronic TB infection is unclear [45]. Still,
experience from animal models has proven detrimental ef-
fects of Tregs during the initial stage of infection [46]. Treg
mediated suppression of effector T cells occurs through
different mechanisms [47] and Tregs may inhibit T cell ef-
fector functions in a COX-2-PGE2 dependent manner
[14]. We find support for the use of COX-i in targeting
Tregs from studies showing that PGE2 induces FOXP3
gene expression and Treg function in human CD4+ T cells
[48]. Both the up-regulation of FOXP3 in Tregs and their
suppressive effect on effector T cells have been shown to
A B
Fig. 4 Effect of indomethacin on TB antigen induced intracellular cytokines in CD4+ T cells. Total IFN-у+, IL-2+ and TNF-α+ T cell responses in
unstimulated (Unstim), ESAT-6 and Ag85 stimulated PBMCs without (open boxes) and with (hatched boxes) indomethacin after 12 h (a, n = 18) and
36 h (b, n = 17) stimulation. PBMCs were obtained from patients with active TB prior to treatment. P- values calculated by Wilcoxon matched pairs
test. Plots are shown as box plots with individual data points with median, IQR and minimum/maximum values. Significant changes between
stimulated samples with and without indomethacin are denoted with p-values in figure
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be reversed by COX- i [14]. To our knowledge there are
no published data of immune therapy aiming to modulate
Tregs in human TB disease. There is however an ongoing
phase I/II clinical trial on COX-2-i in active TB where
Tregs will be studied (ClinicalTrials.gov Identifier: NCT0
2503839). An additional clinical trial aims to reduce the
risk of developing active TB by oral supplementation of a
probiotic containing heat-killed environmental mycobac-
teria (ClinicalTrials.gov Identifier: NCT02076139). Pre-
clinical animal models to this study have shown that the
mycobacteria delay progression to active TB in mice by
inducing PPD specific Treg populations [49]. Nevertheless,
we claim that our observed reduction of FOXP3 in indo-
methacin treated Tregs may be beneficial to the host, shift-
ing the balance towards a more effective immune response
in long-lasting and advanced TB disease.
Animal models also support PGE2 as a significant factor
in the pathogenesis of a dysfunctional hyperactivated
immune system in TB, concluding with beneficial effects of
COX-i with suppressed PGE2 concentrations; reductions
in pulmonary inflammation and bacillary load, reversal to a
Th1 cell profile and improved survival of TB infected mice
A
B
Fig. 5 Mtb antigen induced single, duo and polyfunctional cytokine producing CD4+ T cells. PBMCs were obtained from patients with active TB prior to
treatment and left unstimulated or stimulated with ESAT- 6 or Ag85 without (open boxes) or with indomethacin (hatched boxes) after 12 h (a) and 36 h
(b) stimulation (n= 18 and n= 17 respectively). Boolean gating strategy was used to create cytokine combinations of single-producing, duo-producing
and polyfunctional T cells. P- values were calculated by Wilcoxon matched pairs test ( *p <0.05, **p < 0.01). Plots are shown as box plots with median, IQR
and minimum/maximum values
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[21–24]. In contrast, one study reports reductions in mor-
bidity and mortality by augmenting PGE2 levels in Mtb-in-
fected mice [25]. The conflicting reports may be due to
differences in time since TB infection, emphasizing the
need to be aware of differential effects of PGE2 in recently
versus chronically TB infected mice.
Both CD4+ and CD8+ cytokine producing T cells play
a major role in protection and immunity against TB
disease [50], but contrasting results have made it diffi-
cult to define protective TB immunity based on cytokine
responses [51–53]. In previous clinical trials, we have
shown that HIV infected patients on antiretroviral therapy
experience an improved immune response with concomi-
tant treatment with COX2-i [26–28]. In the present study,
the COX-i indomethacin modestly reduced the Mtb anti-
gen induced CD4+ and CD8+ cytokine responses as well
as the proliferative capacity of the T cells. Our data show
that in particular the CD4+TNF-α+ cell subsets were sig-
nificantly reduced when treated with indomethacin, but
still with detectable levels. Experience from animal models
show that TNF-α is important for control of TB [54, 55]
and treatment with TNF-α blockers have been associated
with the progression from latent to active TB in humans
[56, 57]. TNF-α is essential for maintenance and formation
of the granuloma, but excess TNF-α production also con-
tributes to increased inflammation and pathology in TB
[58]. Thus, one of the purposes of immune modulating
therapy may be to decrease pathology related to excess
TNF-α production while maintaining adequate TNF-α
levels necessary for containment of Mtb [59]. Accordingly,
the decreased levels of TNF-α producing CD4+ T cells
observed in our study may constitute a potential beneficial
response in a setting with chronic untreated TB disease.
The observed reduction of cytokines and proliferative
capacity of T cells may be due to the direct effects of
indomethacin inhibiting activation of the intracellular
NF-κB pathway [60]. The NF-κB pathway is a key medi-
ator of genes involved in the control of cellular prolifera-
tion and apoptosis [61]. Inhibition of the NF-κB pathway
may be involved in the anti-inflammatory as well as the
growth inhibitory properties of certain COX-i [62, 63]
and COX-i have also been reported to inhibit NF-κB
activation in cell culture [64]. In TB, reports have shown
that TNF-α-induced NF-κB signaling pathway is central
to the Mtb-specific immune response, and regulation of
intracellular NF-κB signaling dynamics may be a key to
control TB infection [65]. Thus, in summation, one must
consider that COX-i may exert a relatively stronger
A B
Fig. 6 Effect of Indomethacin on CD4+ and CD8+ T cell proliferation. Proliferative responses measured by percentages of CFSEdim in unstimulated,
ESAT-6 and Ag85 stimulated PBMCs without (open boxes) and with (hatched boxes) indomethacin after 6 days stimulation. PBMCs were obtained from
patients with active TB prior to treatment. a CD4+ T cells (n = 23). b CD8+ T cells (n = 23). P- values were calculated by Wilcoxon matched pairs test.
Plots are shown as box plots with individual data points with median, IQR and minimum/maximum values. Significant changes between stimulated
samples with and without indomethacin are denoted with p-values in figure. %CFSEdim cells were significantly upregulated upon stimulation with
both E6 and Ag85 (p < 0.001, values not shown in figure)
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inhibitory effect on the Th1 effector cells than the antici-
pated beneficial indirect effect following reduced Treg
numbers.
There are limitations to our study. First, the relatively
small number of patients gives reduced power in the
statistical calculations and increases the risk for Type II
statistical errors. Second, multiple testing increases the risk
of type I errors. As there is no gold standard for how to
handle multiple comparisons when considering partially
dependent variables a significance level of 0.05 was used.
Due to limited numbers of samples and PBMC’s available,
we were not able to perform sorting of Tregs with more
in-depth mechanistic studies of the potential impact of the
observed decrease of indomethacin treated Tregs. For the
same reason all analysis could not be performed in the
latent TB group. Thus, future studies on COX-i should
include latent TB controls and also investigate the in vivo
effects of COX-i in clinical trials of patients in different
stages of Mtb infection.
Conclusions
In conclusion, our data indicate that indomethacin may be
used to modulate immune responses in TB infection by
reducing the fraction of Mtb specific Tregs with a con-
comitant reduction of Mtb specific cytokine responses and
T cell proliferation in active TB disease. Still, the effects of
COX-i in TB infection need further evaluation in human
models and future clinical trials should be performed to
explore the effects of COX-i as HDT options in different
settings of TB infection and disease.
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